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Pulmonary hypertension is a rare disease characterised by high pulmonary vascular
resistance. Prognosis depends upon mean pulmonary artery pressure at cardiac
catheterisation. Historically, measurements of pulmonary haemodynamics and exercise
capacity have been used to detect and monitor disease progression and treatment
response, however these approaches have a number of limitations and deficiencies. We
wondered whether an alternative strategy would be feasible; monitoring the adaptation
response of the heart and pulmonary vasculature to pulmonary hypertension. Magnetic
resonance imaging (MRI) is a new and exciting form of imaging with the potential to
make accurate anatomical and physiological measurements in the cardiopulmonary
circulation. In this thesis we set out to investigate whether anatomical and blood flow
measurements made with MRI can detect and quantify raised pulmonary artery pressure
at cardiac catheterisation. We then looked to see whether MRI has any advantages over
doppler echocardiography, the current gold standard noninvasive investigation.
We enrolled twenty-eight subjects who were undergoing cardiac catheterisation and
doppler echocardiography for investigation of suspected pulmonary hypertension at the
Scottish Pulmonary Vascular Unit between September 1999 and March 2001. We used
MRI to measure right and left ventricular mass, volume, and wall thickness, and aortic
and pulmonary artery diameter. We calculated a novel ventricular mass index by dividing
right ventricular mass by left ventricular mass. We then performed a flow quantification
in the right pulmonary artery to measure mean and peak velocity of blood flow,
acceleration time and ejection time, and calculated the ratio of acceleration time over
ejection time. Finally we attempted to study the changes in these variables following
straight leg raising exercise.
We found that our ventricular mass index (r = 0.81), right ventricular wall thickness (r =
0.83) and the ratio of main pulmonary artery over aortic diameter (r = 0.82) showed
better agreement with mean pulmonary artery pressure than doppler echocardiography (r
= 0.77) with sensitivity and specificity at least as good. We found significant correlations
between right ventricular mass and end-diastolic volume with left ventricular mass (r =
0.53 and r = 0.83 respectively). This suggests either an association between pulmonary
4
hypertension and left ventricular hypertrophy or a survival advantage in those with more
massive left ventricles, perhaps due to decreased ventricular compliance protecting left
ventricular filling. Mean and peak velocity of blood flow in the right pulmonary artery
were sensitive and specific markers of the presence ofpulmonary hypertension, but not of
severity. Contrary to the published literature, acceleration time and the ratio of
acceleration time over ejection time did not correlate with pulmonary artery pressure. We
were able to detect changes in all right pulmonary artery blood flow variables in a small
number of subjects after exercise, but we encountered some practical difficulties and the
significance of these observations is uncertain.
In summary, we have shown that anatomical measurements made in the cardiopulmonary
circulation with MRI can be used to estimate pulmonary artery pressure with greater
accuracy than doppler echocardiography. These estimates are likely to be more reliable
than those provided by echocardiography, and may also give a measure of the recent
burden of pulmonary vascular disease. An analogy may be made with the use of
glycosylated haemoglobin instead of glucose in diabetes; pulmonary artery pressure
fluctuates on a minute by minute basis whereas anatomical measurements reflect
sustained changes in pulmonary haemodynamics. It should be said that this approach to
the detection and monitoring of pulmonary hypertension has not yet been fully validated.
Further work needs to be done to test whether it is sensitive to change in longitudinal
follow-up and address the issue of inter and intraobserver reproducibility. Finally, we
have also shown that MRI measurements of blood flow are sensitive and specific
indicators of pulmonary hypertension, and that it may be possible to use MRI to study
exercise-related changes in blood flow.
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1 Introduction
1.1 Historical perspective: from the first to the third millenium
The first person to accurately describe the pulmonary circulation was Ibn An-Nafis, a
physician who lived in Cairo in the 13th Century. He observed that the pulmonary artery
carried blood from the right side of the heart to the lungs, where it was allowed to mix
and combine with air in the alveoli before returning via the veins to the left side of the
heart. The function of the pulmonary circulation as the source of oxygen uptake and
carbon dioxide disposal was not worked out until the 17th and 18th centuries. Major
differences in physiology and regulation between the systemic and pulmonary
circulations, such as the response to hypoxia, were not recognised until much more
recently with the advent of invasive haemodynamic monitoring. In the past two decades,
doppler echocardiography has provided us with a useful means of making measurements
in the pulmonary circulation non-invasively.
This is an exciting time to be a pulmonary vascular physician. Throughout the 20th
century, established pulmonary vascular disease resulting in pulmonary hypertension has
been regarded as untreatable and almost universally fatal. This therapeutic nihilism has
meant that there has been a relative lack of interest in improving diagnostic techniques
because there seemed to be little point in making the diagnosis since we could not alter
the course of the disease. This began to change with the development of novel surgical
approaches and the advent of continuous intravenous prostacyclin therapy, but this was
only of benefit to a small number of patients. However, in the past few years there have
been six randomised placebo-controlled studies of a range of new medical treatments,
four with positive results. It has become obvious that we need a reliable and accurate
non-invasive method ofmaking measurements of pulmonary haemodynamics, a role that
has only been partially fulfilled by doppler echocardiography. This has led to a
resurgence in interest in diagnostic methods and was the stimulus for this thesis.
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1.2 The healthy pulmonary circulation
1.2.1 Anatomy
1.2.1.1 The right ventricle
The normal right ventricle is an elliptical thin-walled structure wrapped around the more
muscular and symmetrical left ventricle. This is a result of the much greater pressures
generated by the left ventricle during systole which cause the interventricular septum to
protrude into the right ventricular cavity. Similarly the left ventricular wall is about eight
times as thick as the atrial walls, whereas the right ventricular free wall is only about
three times as thick. The right atrium is situated at the base of the ventricle and forms the
right margin of the heart. The right side of the heart receives its blood supply from the
right coronary artery and the anterior interventricular branch of the left coronary artery.
Blood drains into the right atrium via the superior and inferior vena cavae, enters the right
ventricle through the tricuspid valve during diastole and is ejected during systole.
1.2.1.2 The pulmonary vasculature
Two distinct arterial and venous circulations serve the lungs. The main pulmonary artery
arises from the base of the right ventricle and is approximately five centimetres long. It
divides into the right and left pulmonary arteries which then divide many more times to
form the pulmonary capillary bed. The right pulmonary artery is longer and straighter
than the left, passing below the arch of the aorta into the right hemithorax. The function
of the pulmonary arteries is to deliver deoxygenated blood from the right ventricle to the
lungs for gas exchange to take place. Oxygenated blood then drains back into the left
atrium by four pulmonary veins. At any one time, the blood volume of the lungs is
approximately 450 ml, 70 ml of which is in the capillaries and the remainder shared
between the arteries and veins.
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The bronchial arteries arise from the descending aorta and its branches and therefore
carry oxygenated blood. They carry about one to two percent of cardiac output and
supply pulmonary tissues down to the level of the respiratory bronchiole. The bronchial
veins drain into the left atrium via the pulmonary veins.
1.2.2 Physiology
1.2.2.1 Pulmonary artery pressure
The pressures at rest in the pulmonary circulation are shown in Table 1A with left sided
pressures for comparison. These pressures can all be measured by catheterisation of the
right and left circulation apart from left atrial pressure which can only be directly
measured by percutaneous means. It can however be estimated from the capillary wedge
pressure (section 1.4.3.1). Systolic pulmonary artery pressure can also be indirectly
estimated by doppler echocardiography (section 1.4.3.2.1).
The lungs are unique in that they accommodate a blood flow equal to that of all the other
organs in the body. The cardiac output of the right ventricle is essentially equal to that of
the left. This coupled with the nine-fold difference in blood volume between the
pulmonary and systemic circulations would be expected to result in a high pressure
system were it not for the low compliance of the pulmonary circulation. The pulmonary
arteries are all thin and distensible, and although relatively short, have much larger
diameters than their counterparts in the systemic circulation. The wall thickness of the
main pulmonary artery is only twice that of the venae cavae and a third that of the aorta.
Furthermore, about half the blood volume ejected by the right ventricle is simultaneously
emptied into the capillaries, veins and left atrium, thus preventing an even higher pulse
pressure. The right ventricle cannot tolerate large acute rises in systolic pressure without
failing, however pressures as high as those seen in the systemic circulation are sometimes
seen in chronic disease.
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Table 1A: Normal pressures in the cardiopulmonary circulation (mmHg)
Mean Systolic Diastolic
Right atrium 2 - -
Right ventricle - 25 0
Pulmonary artery 15 25 9
Pulmonary capillary pressure 7 - -
Pulmonary capillary wedge pressure 5 - -
Left atrium 2-3
Left ventricle - 120 0
Aorta 120 80
1.2.2.2 Cardiac output
Cardiac output at rest is approximately 5L/min. It can be calculated as follows:
Cardiac output = Stroke volume x Heart rate
To account for variation in body size, it is often expressed as cardiac index as follows:
Cardiac index = Cardiac output
Body surface area
• • •• • • "7 •
Giving an average cardiac index of approximately 3L/min/m . Cardiac output varies
widely with activity level and can be difficult to measure accurately and reproducibly. It
is usually measured with a pulmonary artery catheter but a number of non-invasive
methods are available. Cardiac output is governed by the need to deliver an adequate
supply of oxygen to the tissues and is therefore regulated by a number of factors,
including the autonomic nervous system, local tissue metabolism and venous return, in
accordance with the Frank-Starling law.
An alternative approach is to measure ejection fraction which is the percentage of
ventricular volume at the end of diastole that is actually ejected during systole. This is
normally estimated non-invasively using echocardiography but can be calculated by
invasive means. Not all the blood leaving the right ventricle under resting conditions
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enters the pulmonary circulation; it is possible to demonstrate a mild degree of
physiological tricuspid regurgitation in a large proportion of normal people using
echocardiography (1).
1.2.2.3 Resistance
Another useful measurement in clinical practice is resistance, which can be calculated
using Ohm's law in two ways:
Total pulmonary resistance:
= Mean pulmonary artery pressure (mmHgl
Cardiac output (L/min)
Pulmonary vascular resistance:
= (Mean pulmonary artery pressure - Pulmonary capillary wedge pressure) CmmHg)
Cardiac output (L/min)
Total pulmonary resistance is a measure of the total resistance experienced by the right
ventricle including the left heart, whereas pulmonary vascular resistance is a measure of
the resistance due to the pulmonary circulation alone.
1.2.2.4 Physiological shunt
In normal individuals, blood in the aorta has a p02 about 2 mmHg less than that of blood
which has just equilibrated with alveolar air. This is because approximately 2% of blood
leaving the left ventricle has bypassed the pulmonary capillaries and therefore not been
oxygenated. This is mostly explained by the bronchial circulation draining into the left
side of the heart, but there is further dilution of the oxygenated blood in the left ventricle
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by blood that flows from the coronary arteries directly into the chambers of the left heart
via the thebesian veins.
1.2.3 Homeostasis
Pulmonary haemodynamics are actively controlled by a number of factors which are not
discussed in detail here. The endothelium produces several vasoactive factors including
Nitric oxide, endothelins, prostaglandins, leukotrienes, thromboxane and platelet
activating factor. The pulmonary circulation responds to hypoxia with vasoconstriction,
unlike the systemic circulation (2). Neural and humoral factors are also involved,
although they are thought to play a minor role. Cardiac output, gravity and lung volume
provide passive control.
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1.3 Pulmonary hypertension: an overview
1.3.1 Background
The pathological changes of pulmonary hypertension were first described by Romberg in
1891 (3) in a patient with unexplained pulmonary arteriosclerosis. In 1951, Dresdale et al
coined the term primary pulmonary hypertension (4) and widespread awareness of the
disease came with the epidemic of pulmonary hypertension, blamed on the use of the
appetite suppressant aminorex fumarate, that swept Europe in 1967. It took almost 90
years for the first effective medical and surgical treatment to become available, but in the
past ten years there have been dramatic improvements in both quality of life and survival
with the use of calcium channel blockers and prostacyclin. This has led to increasing
recognition of the important role that pulmonary vascular disease plays in many disease
processes, and renewed interest in early diagnosis and intervention.
1.3.2 Definition and classification
Pulmonary hypertension (PAHT) has been defined as a mean pulmonary artery pressure
of over 25 mmHg at rest or 30 mmHg during exercise at right heart catheterisation (5). It
has traditionally been classified as either primary or secondary after clinical assessment
(Table IB), but the realisation that the underlying pathological abnormalities in some
types of secondary disease were very similar to those seen in primary pulmonary
hypertension prompted a new classification based upon histology (Table 1C). This was
proposed at the second World Health Organisation symposium held in Evian, France in
1998 (6). To avoid confusion, the traditional classification will be used throughout this
work unless otherwise indicated, since this has been used almost exclusively in the recent
literature.
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Table 1B: Traditional classification of pulmonary hypertension
Primary Pulmonary Hypertension
(including Familial disease)
Secondary Pulmonary Hypertension due to:
Connective Tissue Disease
- Scleroderma/CREST syndrome
Mixed connective tissue disease
Overlap syndrome
Systemic lupus erythematosa
Chronic Hypoxic Lung Disease








- Venticular septal defect


















Table 1C: New WHO classification of pulmonary hypertension 1998
1. Pulmonary Arterial Hypertension




(a) Collagen Vascular Disease






(f) Persistent Pulmonary Hypertension of the Newborn
(g) Other
2. Pulmonary Venous Hypertension
2.1 Left-Sided Atrial or Ventricular Heart Disease
2.2 Left-Sided Valvular Heart Disease
2.3 Extrinsic Compression of Central Pulmonary Veins
(a) Fibrosing Mediastinitis
(b) Adenopathy / Tumours
2.4 Pulmonary Veno-Occlusive Disease
2.5 Other
3. Pulmonary Hypertension Associated with Disorders of the Respiratory System
and/or Hypoxaemia
3.1 Chronic Obstructive Pulmonary Disease
3.2 Interstitial Lung Disease
3.3 Sleep Disordered Breathing
3.4 Alveolar Hypoventilation Disorders
3.5 Chronic Exposure to High Altitude
3.6 Neonatal Lung Disease
3.7 Alveolar-Capillary Dysplasia
3.8 Other
4. Pulmonary Hypertension due to Chronic Thrombotic and/or Embolic Disease
4.1 Thromboembolic Obstruction of Proximal Pulmonary Arteries
4.2 Obstruction of Distal Pulmonary Arteries
(a) Pulmonary Embolism (thrombus, Tumour, OVA and/or parasites,
Foreign Material)
(b) In-situ Thrombosis
(c) Sickle Cell Disease






5.2 Pulmonary Capillary Hemangiomatosis.
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1.3.3 Histology
Three pathological patterns are seen in Primary Pulmonary Hypertension (PPH);
plexogenic arteriopathy, thrombotic arteriopathy and veno-occlusive disease (7-9),
although the latter has now been reclassified in the most recent WHO report (6).
Plexogenic arteriopathy is characterised by the plexiform lesion, which consists of a mass
of disorganised vessels associated with endothelial cells, smooth muscle cells and
fibroblasts. It is also seen in secondary PAHT associated with collagen vascular disease,
congenital heart disease and portopulmonary hypertension. In thrombotic arteriopathy
there is evidence of old recanalised thrombus appearing as fibrous webs, thought to be
due to either recurrent microembolism or in-situ thrombosis. In veno-occlusive disease
there is widespread intimal proliferation of the intrapulmonary veins and venules,
occasionally extending to the arteriolar bed.
1.3.4 Pathophysiology and natural history
As described earlier, the normal pulmonary circulation is a remarkably adaptable and
compliant system, allowing for large variations in blood flow with relatively small
changes in resistance and pulmonary artery pressure. This flexibility is gradually lost in
the face of progressive vascular damage caused by a recurrent acute insult or an intrinsic
disease process, and results in increased pulmonary vascular resistance. The right
ventricle responds to this by hypertrophy, initially maintaining cardiac output and left
ventricular filling pressure, albeit at the expense of a rise in pulmonary artery pressure
which further damages the pulmonary endothelium. Right ventricular ischaemia may
develop due to increased workload and insufficient coronary blood flow. Eventually the
right ventricle begins to dilate and fail, mechanically compromising left ventricular
function and leading to a fall in cardiac output. Death results from progressive right
ventricular failure and arrhythmias.
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1.3.5 Epidemiology
Primary pulmonary hypertension is a rare disorder, with an estimated incidence of one to
two cases per million people per year. It is commoner in women (ratio 1.7:1) (5), perhaps
due to a lower survival rate of male foetuses with the disease (10), and the mean age at
the time of diagnosis is in the mid thirties. Untreated, the prognosis is bleak with a three
year survival of 48% in one large series (11). The familial form of the disease probably
accounts for 6% (5) and is indistinguishable clinically from the sporadic form (8). It is
inherited in an autosomal dominant fashion with incomplete penetrance, and displays
genetic anticipation (10). The causative gene has been mapped to chromosome 2q 31-32
(12) and has recently been identified as a mutation of the BMPR2 gene which codes for
the type 11 bone morphogenetic protein receptor (13, 14). At least 26% of sporadic cases
display similar mutations (15).
The overall incidence of secondary pulmonary hypertension is unknown, but has been
estimated at 0.5% to 53% depending upon the underlying disorder (Table 1D)(9, 16, 17).
Little is known about prognosis in different types of secondary disease, although the
outlook for connective tissue disease seems poor (16).
1.3.6 Treatment
1.3.6.1 Medical
Vasodilators are the mainstay of treatment for pulmonary hypertension. Calcium channel
blockers are effective in a minority of patients who respond to an acute trial of
vasodilators in the cardiac catheter laboratory — so called "responders" (18-22). Long
term treatment with continuous intravenous prostacyclin improves exercise capacity and
survival in both "responders" and "non-responders" (23-32). Treprostinil, a prostacyclin
analogue given by continuous subcutaneous infusion (33, 34), nebulised iloprost (35),
another prostacyclin analogue with a longer half-life and bosentan (36, 37), an endothelin
antagonist have recently been shown to improve exercise capacity in placebo controlled
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studies but their effect on survival is unknown. Uncontrolled studies have also reported
short-term improvement in pulmonary haemodynamics with oral beraprost (38), oral
sildenafil (39, 40) and inhaled nitric oxide gas (41). There is good evidence from post
mortem and subgroup analyses that anticoagulation also improves survival (7, 20, 42).
Table 1D: Estimated prevalence of secondary pulmonary hypertension
Disease/condition Prevalence
Connective tissue diseases overall
CREST syndrome


















? 0.5 - 2%
? 0.5 - 2%
? 25 - 50 per million
1.3.6.2 Surgical
Transplantation is the most established of the three surgical options currently available
for this disease. The first successful heart-lung transplantation was performed in a patient
with primary pulmonary hypertension (43). Operative mortality ranges from 16-29%
depending upon aetiology with one, three and five year survival between 70-75%,, 55-
60% and 40-45% respectively (6). The timing of referral to a transplant centre remains a
difficult issue, especially in the light of recent advances in medical therapy.
Atrial septostomy was first performed by Rich and Lam in 1983 (44), and since then
several investigators have reported a beneficial effect on pulmonary haemodynamics
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(45-48). The rationale is to artificially create a right to left shunt thereby increasing
cardiac output and systemic oxygen delivery, and reducing right atrial pressure.
Unresolved issues include mechanism of action, optimal timing of intervention, choice of
technique (blade balloon or graded balloon dilation), and long term effects (49).
Pulmonary thromboenderarterectomy is very effective in carefully selected patients with
proximal thromboembolic disease demonstrated at angiography. Surgery results in an
increase in pulmonary blood flow and cardiac output, extended survival, and improved
quality of life (50).
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1.4 Monitoring the pulmonary circulation
1.4.1 The importance of monitoring
The pulmonary circulation is frequently involved in systemic and cardiorespiratory
disease. Bedside clinical assessment is a poor measure of disease severity (51), and an
objective assessment of the cardiopulmonary circulation is often required to monitor
disease progression and the response to treatment. Ideally these measurements would be
noninvasive and allow us to predict mortality and guide the timing of surgical referral.
This has become increasingly important with the advent of effective therapy, since
pulmonary hypertension is now considered a treatable disease. The development of novel
medical and surgical approaches to treatment means that we need a method of making
regular reliable objective measurements of the burden of disease, both for clinical trails of
these new therapies and for clinical practice.
1.4.2 Which endpoints should we measure?
The traditional approach has been to measure pulmonary haemodynamics, namely
pulmonary artery pressure, cardiac output and resistance. We know that reliable and
reproducible measurements can be made invasively during cardiac catheterisation. This
has been further refined with the use of ambulatory pulmonary artery pressure monitoring
which has revealed significant postural and diurnal variation (52). These measurements
have been shown to give useful prognostic information (11), but the timing of surgery, in
particular transplantation, remains difficult. In any case, cardiac catheterisation is
invasive, potentially hazardous, and requires hospital admission, and is therefore
unsuitable for frequently repeated measurements.
Unfortunately there is no simple sphygmomanometer for the pulmonary circulation and
accurate reproducible non-invasive measurements have been difficult to make. The most
widely used method at present is doppler echocardiography, but this has a number of
limitations that will be discussed later.
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An alternative approach, adopted by many of the recent trials of new therapies, has been
to measure exercise tolerance. This has been done by means of the six minute walk test,
the shuttle walk test and cardiopulmonary exercise testing.
1.4.3 Measuring pulmonary haemodynamics
1.4.3.1 Right heart catheterisation
1.4.3.1.1 Pulmonary artery pressure
The definitive method of assessing pulmonary haemodynamics is right heart
catheterisation, first performed by Lewis Dexter in 1945 (53). This is done by passing a
pulmonary artery catheter into the great veins via an internal jugular, subclavian, femoral
or brachial approach, and guiding it into the right atrium, ventricle and pulmonary
arteries under fluoroscopic guidance. Dexter showed that this technique could be used to
measure pressure and oxygen saturation in the great veins and right heart chambers as
well as in the pulmonary artery. He later showed that an estimate of left atrial filling
pressure, the "wedge pressure", could be obtained by transiently occluding a distal branch
of the pulmonary artery, assuming the presence of an uninterrupted column of blood
between catheter tip and left atrium (54). The technique was refined in 1970 by Swan et
al with the introduction of the balloon tipped catheter (55), which could be inserted at the
bedside without the need for fluoroscopy. Right heart catheterisation, usually performed
in a cardiac catheter laboratory (Figure 1 A), is now a routine procedure at specialist units,
but it is not without its risks. There is significant morbidity and the incidence of life-
threatening complications is approximately 0.5-1% in this patient group (42, 56, 57),
rising to 2-4% if pulmonary angiography is also performed (58, 59).
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Figure 1A: Cardiac catheter laboratory
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1.4.3.1.2 Cardiac output
There are principally two methods by which cardiac output can be measured with a
cardiac catheter, the direct Fick method and the indicator dilution method.
Fick method
The Fick principle states that the amount of a substance taken up by an organ must be
equal to the arterial concentration minus the venous concentration multiplied by the blood
flow. This can be applied to the uptake of oxygen by the lungs as follows:
Volume of 02 taken up (V02 ml/min)
= Arterial 02 concentration (pa02 ml/L) — Venous Q2 concentration (pv02 ml/L)
Cardiac output (CO L/min)
Or:
CO (L/min) = paQ2 (ml/L) - pvQ2(ml/L)
V02 (ml/min)
A sample of venous blood is taken, preferably from the pulmonary artery to minimise the
risk of incomplete mixing and the effect of left to right shunts. Blood is also taken from a
peripheral systemic artery, while oxygen uptake is simultaneously determined by means
of a metabolic cart or reservoir bag technique. The method is accurate but clearly time
consuming and invasive. It has become the method of choice in determining CO in the
presence of shunting, such as in congenital heart disease.
Indicator dilution method
In the indicator dilution technique, a known quantity of indictor is injected into a large
vein or preferably into the right heart or pulmonary artery itself. Repeated samples of
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peripheral systemic arterial blood are taken and the concentration of indicator plotted on
a graph against time. The initial decline in concentration is extrapolated to the x-axis to
give the time taken for the entire bolus of indicator to pass the arterial sampling point,
and the mean indicator concentration during that time period is then calculated. Total CO
in litres for that time period is then equal to the amount of indicator injected divided by
its mean arterial concentration, and CO in litres per minute can then be calculated. The
method is limited by the need for a non-toxic indicator that remains in the blood stream
and does not accumulate in body tissues during repeated measurements, such as
indocyanine green.
Thermodilution
A refinement of indicator dilution is the technique of thermodilution, which was first
described by Fegler et al in 1954 (60). A number of subsequent animal studies
demonstrated its practicality and reliability (61, 62), however it was not used in human
subjects until Ganz et al showed in 1971 that it was much simpler than indicator-dye
dilution with similar accuracy and reproducibility (63). The balloon-tipped pulmonary
artery catheter became commercially available shortly afterwards and became the method
of choice (55). Invasive measurements of pulmonary haemodynamics with an indwelling
catheter are now routinely made in the care of critically ill patients and used to guide
management and predict prognosis. The benefits of this approach seemed obvious to
clinicians and were never subjected to objective assessment. Recently however there has
been increasing evidence of significant associated mortality and morbidity in the acute
setting (64) and there have been growing calls for a moratorium on their use until an
adequate randomised controlled trial has been undertaken.
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1.4.3.2 Doppler echocardiography
1.4.3.2.1 Pulmonary artery pressure
Three methods of assessing pulmonary artery pressure have been described using doppler
echocardiography (Figure IB): continuous wave doppler of the tricuspid valve, pulsed
wave doppler of the pulmonary outflow tract and right ventricular isovolumic relaxation
time.
Continous wave doppler
In 1984 Yock and Pop described a method of assessing pulmonary artery pressure using
doppler echocardiography (65). They pointed out that pulmonary artery systolic pressure
was the same as right ventricular systolic pressure in the absence of a pressure gradient
across the pulmonary valve. They then showed that right ventricular systolic pressure
could be calculated if right atrial pressure and the maximum velocity of tricuspid
regurgitation were known using a modified form of the Bernouilli equation as follows:
Right ventricular to right atrialpressure gradient
2
= 4 x (maximum velocity oftricuspid regurgitation jet)
This shows that the velocity of tricuspid regurgitation depends only upon the pressure
difference between the right ventricle and the right atrium, and not on the geometry of the
valvular orifice. They then measured tricuspid regurgitation by positioning a doppler
ultrasound beam in line with blood flow through the valve, using continuous wave
recordings to determine peak velocity, and estimated right atrial pressure by measuring
central venous pressure (Figure 1C). Conventional echocardiography can then be used to
exclude the presence of a gradient across the pulmonary valve. They applied this method
in a study of 62 patients with clinical signs of right heart failure. Tricuspid regurgitant
37




Figure 1C: Estimation of systolic pulmonary artery
pressure from tricuspid regurgitation jet
using doppler echocardiography
RAP = right atrial pressure, RVP = right ventricular pressure
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jets were clearly recorded in 87% of subjects and right atrial pressure was estimated
clinically from the jugular veins. They reported very close agreement with catheter
measurements (r = 0.93, standard error 8mmHg) although these were not made
simultaneously (65).
A number of studies have reported correlation coefficients of between 0.89 and 0.87 with
cardiac catheterisation in subjects with pulmonary hypertension due to primary disease,
connective tissue disease, congenital heart disease and left heart disease (65-69).
Interobserver variability appears to be less than 3% and measurements are unaffected by
cardiac output (66) Measurements seem to be accurate over a range of pressures (65-69),
however the correlation coefficients do not tell the whole story and can be misleading
(70). The standard error reported in these studies ranges from 5-9 mmHg in comparison
to catheter measurements and both false negative (71) and false positive (69, 72, 73)
measurements have been reported. This difference can be explained in a number ofways.
Catheter and doppler measurements were not made simultaneously in most studies. There
is often uncertainty in measuring the maximum velocity of the tricuspid regurgitant jet
and an unavoidable angle between the jet and the hand held doppler probe (65). The
maximum pressure difference across the tricuspid valve may occur before peak right
ventricular pressure in some situations (65). Furthermore, the frequency response of
fluid-filled pulmonary artery catheters may be too slow for instantaneous measurements
to be made (74). There is also evidence from high fidelity transducer tipped catheter
studies that the assumptions made about the orifice geometry of the tricuspid valve in the
Bernoulli equation are incorrect (71).
A further source of error is the value assigned to right atrial pressure. Yock and Pop
reported only a modest correlation between clinical assessment and invasive
measurement (65). Some authors have used a fixed value ranging between 5 mmHg (75)
and 14 mmHg (68) while others have proposed using the response of the inferior vena
cava to inspiration as a guide (76, 77). Chan et al found that a fixed value of 14 mmHg
gave more accurate results than an estimated pressure (68). Others have not found it
necessary to take right atrial pressure into account to get accurate results (67). This
variation in method makes it difficult to compare the results of different studies.
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Tricuspid regurgitation can be detected in approximately 50% of normal subjects (1) and
almost all those with clinical signs of right heart failure (65, 66), especially in the
presence of a systolic pulmonary artery pressure of more than 50 mmHg (66, 67).
However success rates are lower in the absence of clinical right heart failure (68) and
measurements are not possible in a significant proportion of subjects. Denton et al
reported a failure rate of 39% in subjects with systemic sclerosis due to absence of
suitable tricuspid regurgitation (69). Currie et al found analysable tricuspid regurgitant
jets in only 80% of subjects with raised pulmonary artery pressure (66). Chronic
obstructive pulmonary disease is a particular problem with success rates of only 24 - 66%
in some studies (75, 78) although this can be improved by means of saline contrast
enhancement (76).
Pulsed wave doppler
In 1983, Kitabatake et al used a pulsed doppler technique to study pulmonary artery flow
velocity in a series of 33 subjects, 16 of whom had a mean pulmonary artery pressure of
more than 20 mmHg (79). They measured Acceleration time (AT) defined as the time in
milliseconds between the onset of blood flow through the pulmonary valve and the
maximum velocity of blood flow attained in the pulmonary outflow tract, and Ejection
time (ET), the time between the onset and the end of blood flow through the pulmonary
valve during a cardiac contraction (Figure ID). They found that those with raised
pressure had a shorter AT and that both AT and the ratio of AT/ET correlated well with
mean pulmonary artery pressure (r = 0.88 and 0.9 respectively). In ten of the pulmonary
hypertensive subjects a secondary slower rise was observed, resulting in mid-systolic
notching of the flow velocity contour. Adequate measurements were obtained in 70% of
subjects and 90% of those with raised pressure.
Subsequent studies have confirmed the sensitivity and low failure rate of this technique,
but not all have shown similar accuracy. Isobe et al reported sensitivity and specificity of
93% and 97% respectively with good accuracy irrespective of cardiac output (80). On the
other hand, Dabestani et al reported intraobserver and interobserver variability of 7% and
9% respectively and sensitivity and specificity of 78% and 100% respectively for AT, but
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Figure 1D: Measurement of acceleration time (AT) and










a standard error of the estimate of 8.3mmHg with a correlation of 0.87 (81). Other studies
have reported similar results in studies of primary pulmonary hypertension, chronic
obstructive airways disease, congenital heart disease, left heart disease and connective
tissue disease, with correlations with catheter measurements of between 0.7 and 0.88 for
AT and AT/ET with mean pulmonary artery pressure or its logarithm and higher standard
errors in some cases (82-86). Unlike doppler of the tricuspid regurgitant jet, the success
of this method does not seem to depend upon disease severity and is not diminished in
chronic obstructive airways disease (84, 86). In summary, pulsed doppler
echocardiography appears to be a sensitive way of detecting the presence of pulmonary
hypertension but does not consistently allow the accurate quantification of pulmonary
artery pressure (87).
Isovolumic relaxation time
In 1967, Burstin et al described a method of indirectly estimating systolic pulmonary
artery pressure from external graphic recordings (88). Using a jugular phlebogram to
determine tricuspid valve opening and a phonocardiogram to determine pulmonary valve
closure, he measured the isovolumic relaxation time of the right ventricle, defined as the
interval between pulmonary valve closure and tricuspid valve opening. He was then able
to predict peak pulmonary artery pressure by means of a nomogram that took account of
heart rate. Hatle et al modified this techique in 1981, by using continuous wave doppler
to study flow velocity wave forms in the tricuspid and pulmonary valves using cessation
of flow in the latter and initiation of flow in the former to measure isovolumic relaxation
time, and consequently pressure using Burstin's nomogram (89). Stevenson et al applied
this technique in a study of 95 infants and children and reported a correlation coefficient
of 0.86 unsedated and 0.96 sedated in comparison with cardiac catheterisation (90). A
heart rate of more than 155 beats/min was associated with reduced accuracy. In a recent
study, Caso et al were able to distinguish normal subjects, subjects with chronic
obstructive lung disease and subjects with chronic obstructive lung disease and
pulmonary hypertension (91).
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Which method is best?
A number of studies have compared the accuracy of these methods (68, 78, 92). Chan et
al studied fifty patients with a variety of conditions including primary pulmonary
hypertension, cardiac valve disease and congenital heart disease (68). They reported a
success rate of 72%, 88% and 22% using continuous wave doppler, pulsed wave doppler
(AT) and isovolumic relaxation time respectively. Overall accuracy was better for
continuous wave doppler (r = 0.89) than pulsed wave doppler (r = 0.65), but the latter
improved in accuracy when only patients with a heart rate of between 60 and 100
beats/min were included (0.85). The low success rate using isovolumic relaxation time
was due to the high incidence of arrhythmia. Torbicki et al performed a similar study in
72 patients with chronic lung disease (78). Continuous wave doppler was successful in
only 17 patients with a correlation coefficient of 0.92. AT measured by pulsed doppler
was successful in 68 out of 72 with a correlation coefficient of 0.72, a standard error of
8.3 mmHg and a positive predictive value for pulmonary hypertension of 84%.
Isovolumic relaxation time succeeded in 59 out of 72 subjects with a correlation of 0.69
and a standard error of 12.3 mmHg. Chow et al found that continuous wave doppler
predicted the change in pressure more reliably than pulsed wave doppler after pulmonary
thromboendarterectomy (92).
No single doppler method provides accurate measurements in all patients. Chan et al
showed that in 96% of patients at least one method was feasible (68). Continuous wave
doppler appears to be the most useful and practical method because it allows more
accurate quantification of pressure than pulsed wave doppler, and does not require a
nomogram. It has now become the gold standard non-invasive method of assessing
pulmonary artery pressure, and has made the screening of small numbers of "at risk"
patients possible.
1.4.3.2.2 Cardiac output
Echocardiography can be used to measure stroke volume using Simpsons rule (Figure
IE). The ventricle is taken to be a cylinder and divided up into rings of the same
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Figure 1E: Calculation of stroke volume using
Simpson's rule
Volume of ventricle = Sum of volume of holes in 'rings'
Stroke volume = End-Diastolic volume - End-Systolic volume
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thickness. The area of the "hole" in the ring is multiplied by the thickness to get the
volume. The volume of all the holes in the rings is then added up to give an estimate of
ventricular volume. This process is done in end-systole and end-diastole, and the former
subtracted from the latter to obtain stroke volume. This is then multiplied by heart rate to
obtain cardiac output. This requires considerable technical expertise and is often
inaccurate due to left ventricular asymmetry because a two dimensional view of the left
ventricle is extrapolated to derive three dimensional volumes. In addition measurements
are difficult to obtain and standardise with changes in posture and physical activity.
A wide range of echocardiographic approaches have been described for the measurement
of cardiac output using Doppler echocardiography, mostly in an Intensive or Coronary
Care setting, using different cardiac locations and time-velocity integral measurements.
Transoesophageal and transtracheal approaches have also been developed which have
increased accuracy and reproducibility and several studies have shown a favourable
comparison with thermodilution (93-97). In general Doppler echocardiography appears to
be a useful method of monitoring trends in cardiac output in a controlled setting, but
varying posture and inter-observer variability limit its accuracy for outpatient use. There
is a need for an accurate, reproducible and minimally invasive method of assessing
cardiac output.
1.4.4 Measuring exercise tolerance
1.4.4.1 Six minute walk test
Simple tests of exercise tolerance, ofwhich this is the most widely used, are a useful way
of detecting and monitoring changes in functional capacity due to cardiorespiratory
disease and have the advantage of relating directly to the symptoms experienced by
patients. The six minute walk test is very simple, requires inexpensive and easily
available equipment, and is reproducible. It is a submaximal exercise test whereby the
patient is asked to walk at a comfortable pace for six minutes along a measured course,
usually with simultaneous pulse oximetry. The distance walked is recorded as well as the
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heart rate and the degree of desaturation. The test is considered to be safe because it is
self-limited and reflects the demands of everyday living (11, 98).
Performance in the six minute walk predicts survival in left ventricular dysfunction and
advanced heart failure (99, 100). In 1996 Barst et al reported similar findings in 81
patients with primary pulmonary hypertension with NYHA III or IV and suggested that
this test could be used to monitor individual patients (27). Miyamoto et al confirmed this
finding, but only found weak correlations between distance travelled and cardiac output
and total pulmonary resistance, and no correlation with mean pulmonary artery pressure
(101). Longterm treatment with vasodilators improves performance during the six minute
walk (27, 34, 36, 37), sometimes with minimal improvement in pulmonary
haemodynamics (34).
Limitations of this form ofmonitoring are that results are easily influenced by the level of
encouragement given by the tester, and by the cooperation and motivation of the patient.
There is a also a clear learning curve, with some investigators incorporating one or more
"Practice walks" into the study protocol to overcome this (34). Furthermore, the
prognostic value of the six minute walk test has not been clearly established in subjects
with NYHA I or II, or in those with secondary pulmonary hypertension, many of whom
have significant comorbidity such as arthritis.
1.4.4.2 Cardiopulmonary exercise testing
Exercise testing with simultaneous gas exchange, electrocardiogram (ECG) and blood
pressure measurements only became a practical process with the recent development of
computers able to assimilate the large amount of data generated. Modern systems are able
to calculate and display gas exchange data "live" during exercise, enabling the tester to
continuously assess the adequacy of work rate and making the process safer for the
patient.
There are a number of characteristic abnormalities seen in pulmonary hypertension,
including decreased oxygen uptake and oxygen pulse and increased ventilatory
equivalents (102), but it remains unclear whether any of these indices predict mortality.
Rhodes et al showed that exercise capacity displays a close negative correlation with
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right atrial pressure (57) which is itself a marker of poor prognosis (5), and that poor
exercise capacity predicted mortality at cardiac catheterisation (57). Similarly, there is
little published evidence showing that gas variables derived at cardiopulmonary exercise
testing correlate with resting pulmonary haemodynamics, although there is evidence that
pulmonary artery pressure on exercise correlates with ventilatory equivalents (103, 104).
Thus although some authors have advocated serial exercise testing to monitor this group
of patients (105, 106), more work needs to be done in this area.
1.4.5 Deficiencies of conventional investigation
Pulmonary hypertension is defined as an abnormality of pulmonary haemodynamics (6),
and it is logical to attempt to monitor disease progression and treatment efficacy in terms
of deterioration or improvement in these indices. This approach appears to be validated
by the prognostic information derived from haemodynamic measurements, in particular
right atrial pressure, mean pulmonary artery pressure and cardiac index (11).
The most widely used non-invasive technique, Doppler Echocardiography (65), is safe
and widely available, but has several limitations as discussed earlier. It cannot measure
mean pulmonary artery pressure and only provides an estimate of systolic pressure. It
depends upon the presence of detectable tricuspid regurgitation and has a significant
failure rate in some patient groups (78). Furthermore, measurements are somewhat
operator-dependant, and influenced by physiological variables such as heart rate,
hydration status and posture (52).
Fluid-filled pulmonary artery catheters have remained the gold standard method of
measuring pulmonary artery pressure both for research and for clinical purposes, but are
invasive and also have a number of limitations. The need for leveling an external pressure
transducer with the catheter tip in the right atrium for calibration makes measurements
during exercise and changes in posture difficult. Pressure measurements are not "real¬
time" and the signal may be damped by the fluid-filled lumen (107). Some authors have
also expressed doubts about the relevance of measurements made in unrepresentative
surroundings, arguing that they bear little relation to the pulmonary haemodynamic
variation encountered by patients with everyday activity (107), a criticism that can also
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be leveled at echocardiography. There is significant spontaneous variability in pulmonary
artery pressure at rest (108). Rich et al made measurements of pulmonary
haemodynamics hourly for six hours in twelve subjects with primary pulmonary
hypertension, demonstrating average variability of 8% in mean pulmonary artery pressure
and 13% in total pulmonary resistance (108). We also know from ambulatory
micromanometer-tipped catheter studies that pulmonary artery pressure varies widely
over the course of a twenty-four hour period (52, 103, 109), so it seems unlikely that
these one-off measurements will provide a clinically relevant assessment of pulmonary
haemodynamics. Ambulatory studies have demonstrated a similar phenomenon in the
systemic circulation and guidelines now emphasize the importance of multiple
measurements before anti-hypertensive treatment is initiated or modified. Similarly we
know that cardiac output is a very labile measurement and it is a testament to the
flexibility of the pulmonary circulation that this does not seem to translate into labile
pulmonary artery pressure measurements.
There are a number of other criticisms that can be directed at a purely "haemodynamic"
approach to monitoring these patients. The main symptom of patients with pulmonary
hypertension is exercise intolerance, and this seems to correlate poorly with the degree of
haemodynamic disturbance (101). This suggests the problem is not simply the severity of
pulmonary hypertension but also the way that the heart and pulmonary circulation adapt
or respond to it. This idea is supported by the finding of Raeside et al that pulmonary
artery pressure correlates with ventilatory equivalents when both are measured during
exercise, but that resting pulmonary haemodynamics do not seem to predict exercise
haemodynamics (103). Furthermore, we do not know why some patients maintain cardiac
function while others develop right heart failure in response to similar resting pulmonary
haemodynamics; this also suggests a difference in response of the right ventricle.
Similarly, although exercise capacity appears to predict prognosis, this is only at the
extremes of the scale, and correlation with prognosis is poor for the majority of patients
(57). Miyamoto et al found that performance at six minute walk test predicted mortality
in those patients who walked less than 332 metres, but did not report a direct correlation
between distance walked and survival (101).
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There is already evidence that genetic factors play a part in the adaptation responses of
the right ventricle and pulmonary circulation. A mutation of the BMPR2 gene has been
identified as the causative gene for familial and some sporadic pulmonary hypertension,
however penetrance is incomplete suggesting a role for other factors (12-15). Deletion
polymorphisms in the Angiotensin Converting Enzyme gene are associated with right
ventricular hypertrophy, exercise induced pulmonary hypertension and tissue
oxygenation in chronic obstructive airways disease (110-112). They are also associated
with left ventricular hypertrophy and coronary artery disease (113-115), and the ability of
elite mountaineers to climb above 7000 metres (116).
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1.5 Magnetic resonance imaging
1.5.1 History
The phenomenon underlying MRI was first noticed by Rabi in 1939 who used it to probe
particle beams. His techniques were later refined by Broch and Purcell in the 1940s and
used to analyse the structures of solids and liquids. The first images of the live human
body were obtained by Damadian et al in 1977 (117). Clinicians have not been slow to
realise the implications for medical practice of a form of imaging capable of providing
superb soft tissue resolution and accurate physiological information, all without the risk
associated with X-ray exposure. Over the past two decades two-dimensional, three
dimensional and functional imaging have become possible, and MRI has revolutionised
imaging in cardiology and neurology in particular. As the technology has become less
expensive and cumbersome it has become more widely available, but at the time of
writing still remains the preserve of larger hospitals.
1.5.2 Theory: how does it work?
1.5.2.1 The atomic nucleus
MRI depends upon the ability of the atomic nucleus to absorb and emit energy, and the
consequent variations in its behaviour in response to an externally applied magnetic field.
Atoms are essentially made up of three components; protons and neutrons, which make
up the nucleus, and electrons which orbit the nucleus. There are three forms of motion
within the atom:
1) Spin of the nucleus on its axis
2) Spin of the electrons around their own axes
3) Orbit of electrons around the nucleus
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Nuclear spin of atoms present in tissue provides the basis for MRI. Atomic nuclei with an
odd mass number (sum of protons and neutrons) are "MR active". This is because the
laws of electromagnetic induction state that spinning nuclei with a net charge induce a
magnetic field around them, a "magnetic moment", with a North and a South pole. This
magnetic moment has vector properties and means that the nuclei can be lined up with a
strong external magnetic field.







In clinical MRI the Hydrogen nucleus is used, because its small size gives it a relatively
large magnetic moment, and it is widely present in the human body. The magnetic
moment ofHydrogen is called the Net Magnetisation Vector (NMV).
1.5.2.2 The external magnetic field (Bo)
The unit ofmagnetic field strength is the Tesla (T). Fields in clinical use currently range
between 0.3 T and 2 T. Hydrogen nuclei in biological tissue are usually randomly
aligned. When a powerful magnetic field is applied to the human body, they respond by
lining up either parallel (low energy or "spin up" nuclei) or antiparallel to the field (high
energy or "spin down" nuclei, see Figure IF) There are always more spin up nuclei than
spin down, but the more powerful the field, the larger the proportion of spin up nuclei. At
this point more of the hydrogen nuclei have lined up parallel than antiparallel to the field
and this results in the patient having a Net Magnetisation Vector.
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Figure 1F: Alignment of hydrogen nuclei under
the influence of an external magnetic
field (Bo) resulting in a net
magnetisation vector (NMV)
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1.5.2.3 Precession and resonance
There is always a degree of wobble of the NMV around the axis of the magnetic field,
which is termed precession. The precessional frequency (also called the Larmor
frequency) is defined by the Larmor equation as follows:
Precessional frequency = Bo x y where y is the gyromagnetic ratio which is a
constant for a specific MR active nucleus at 1.0
Tesla
Precession is important because it gives hydrogen nuclei the ability to resonate in
response to pulses of radiofrequency energy, if delivered at exactly the Larmor
frequency. Energy is absorbed and some low energy "spin up" nuclei become high
energy "spin down" nuclei. This is termed Nuclear Resonance or excitation, and has two
effects:
1) The axis of the patient NMY shifts from the longitudinal plane by a
variable degree known as the Flip angle, usually by a full 90° into the
transverse plane.
2) Each individual hydrogen nuclear magnetic moment making up the patient
NMV begins to precess in phase.
1.5.2.4 The MR signal
The NMV is therefore precessing in the transverse plane, creating a moving magnetic
field. According to Faraday's laws of induction, a voltage will be induced in a receiver
coil placed in a moving magnetic field. The voltage induced in such a coil by the
precessing NMV constitutes the MR signal and is the basis for MRI. A Pulse Sequence of
energy at Resonance Frequency (RF) is delivered to the Hydrogen nuclei under the
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influence of the magnetic field, and MR signals are detected in multiple receiver coils
located in the scanner, which allows a three dimensional image to be constructed.
When the energy pulse ends, the patient NMV begins to realign itself once more with the
magnetic field. Magnetisation in the longitudinal plane increases (termed T1 Recovery)
and in the transverse plane decreases (T2 Decay), both in an exponential way. The degree
of T1 Recovery and T2 Decay that take place depends upon the following:
Repetition Time (TR): The time in milliseconds between pulses of energy which
determines the amount of T1 Recovery that has time to occur.
Echo Time (TE): The time in milliseconds from the onset of an energy pulse to
the time of peak signal induction in the coil, thus defining the amount of T2
Decay that has time to take occur.
Each pulse sequence is defined by these two separate timing parameters.
1.5.2.5 How is contrast generated?
The NMV can be divided into longitudinal and transverse components. If the NMV of a
tissue has a relatively large transverse component than it will induce a higher voltage in
the receiver coil resulting in a bright (or white) area on the image. Similarly a small
transverse component results in a dark (or black) area on the image. The Larmor
frequency of hydrogen in fat is lower than in water, resulting in a difference in NMV
between these two tissues and a different MR signal intensity (Figure 1G). Most soft
tissues are made up varying degrees of fat and water, explaining the exceptionally good
resolution that can be obtained with MRI.
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Figure 1G: Contrast is generated by the difference
in transverse and longitudinal components
of NMV between fat and water
Longitudinal component of NMV
Bo
Transverse component of NMV
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As described above, the operator can determine the amount of T1 Recovery and T2
Decay that takes place by setting the TR and TE appropriately:
T1 weighting (bright fat) Short TR (increases Tl)
Short TE (decreases T2)
T2 weighting (bright water) Long TR (decreases Tl)
Long TE (increases T2)
Furthermore, tissues with higher proton density (eg: brain) induce a larger voltage in the
receiver coil, and therefore generate brighter images. Proton density images can be
obtained with the following settings:
Proton density weighting Long TR (decreases Tl)
Short TE (decreases T2)
In summary, contrast depends upon the intensity of the MR signal generated, and this in
turn essentially depends upon three factors: Tl weighting, T2 weighting and Proton
density.
1.5.3 General points
Magnetic Resonance Imaging is an attractive modality for studying the complex
geometry of the right ventricle and pulmonary vasculature since no assumptions need to
be made about the shape or location of the structure being studied. It provides three-
dimensional anatomical measurements of right ventricular morphology that are
unaffected by physiological variables and more likely to be reproducible than dynamic,
planar measurements made at echocardiography. Furthermore, these anatomical variables
reveal the right ventricular response to chronic pulmonary vascular disease and may
provide a more clinically relevant assessment of disease severity.
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MRI has been extensively used to image the left ventricle but there have been relatively
few studies of right ventricular function and morphology. It has been successfully used to
quantify ventricular volumes and estimate ventricular mass in both normal and PAHT
subjects and normal ranges have been established (118-122). Clear abnormalities have
been demonstrated both in right ventricular morphology and function and in the proximal
pulmonary vasculature in PAHT (121-125). Non-invasive assessments of blood flow and
distensibility in the pulmonary arteries can be made (126-128), as well as estimates of
stroke volume and cardiac output (127). Changes in right ventricular mass, function and
pulmonary artery blood flow have been observed following lung transplantation (129-
132), and MRI has been shown to be far more accurate than echocardiography in
monitoring changes in left ventricular mass (133).
1.5.4 Pulmonary artery pressure
Several investigators have attempted to use MRI as a non-invasive means of estimating
mean pulmonary artery pressure (MPAP) using a number of different approaches. Some
studies have reported a "slow flow" phenomenon, with persistent high MR signal
intensity in the pulmonary arteries during systole (123, 125, 134, 135). Didier and
Higgins studied this phenomenon in 15 patients with congenital left to right shunts and 10
normal volunteers. They demonstrated a linear relationship between the intensity of the
MR signal in systole in the right pulmonary artery and pulmonary vascular resistance
(PVR) in those with elevated pulmonary artery pressure. There was an even closer
correlation with the ratio ofPVR over systemic vascular resistance (135). Similarly, Von
Schultess et al reported a good correlation with PVR in PPH (134).
The right ventricle hypertrophies in response to raised pulmonary artery pressure. Right
ventricular end-diastolic wall thickness (RVWT) has been shown to correlate well with
MPAP and PVR in PPH and some causes of secondary pulmonary hypertension
including chronic lung disease, left heart disease and chronic pulmonary embolism (123,
125, 136). Saito et al reported close correlations with MPAP for RVWT and the ratio of
RVWT divided by left ventricular posterior wall thickness (LVPWT) in 36 patients with
chronic lung disease and a range of MPAP from 10-50 mmHg (136). Frank et al
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demonstrated a good correlation with RVWT corrected for body surface area (BSA) in 23
patients with MPAP range 37-75 mmHg (125).
With hypertrophy comes an increase in mass and a linear relationship between right
ventricular mass (RVM) and MPAP has been described for PPH (122). In the largest
series in the literature, Katz et al measured RVM using MRI in 13 subjects with a
diagnosis of PPH, five of whom were under 18 years of age. They used a modified
Simpsons rule to calculate right and left ventricular mass (see General Methods), a
method which they validated by initially scanning and then weighing ten fresh calf hearts.
They derived a right ventricular mass index by correcting for BSA and demonstrated a
good correlation with an r value of 0.75 with MPAP using linear regression analysis
(122). Using a similar method, Turnbull et al reported a correlation of 0.72 between
RVM and MPAP in 16 subjects with moderate/severe COPD with MPAP 30 +/- 10
mmHg (137).
An alternative approach has been to measure the diameters of the great vessels. This was
based upon the theory that raised pulmonary artery pressures would lead to proportional
distension of the pulmonary arteries and great veins emptying into the right atrium, and
furthermore that the consequent reduction in cardiac output would result in reduced aortic
diameter. Studies have reported correlations between MPAP and main pulmonary artery
diameter (MPAD) (125, 138-141) and diameter of inferior vena cava (125). Murray et al
measured the ratio of MPAD over descending Aortic diameter (MPAD/AOD) in 12
patients with PPH (MPAP 59.6 +/- 19.0 mmHg) within one week of cardiac
catheterisation (124). Although overall agreement was poor, they were able to report an r
value of 0.7 for MPAD/AOD due to the wide range of MPAP in their study population.
Ng et al reported the results of a similar study using CT in 50 patients with a wide range
of pulmonary and cardiovascular diseases and found a strong correlation between
MPAD/AOD and MPAP, especially in patients younger than 50 years(l 39).
1.5.5 Cardiac output
Two main approaches have been used to measure cardiac output using MRI: firstly by
calculation of stroke volume and ejection fraction using Simpsons rule by subtracting
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systolic ventricular volume from diastolic ventricular volume, and secondly by measuring
blood flow through the great vessels or the cardiac valves. Studies have been limited by
the difficulty in obtaining simultaneous invasive measurements of cardiac output since
conventional thermodilution cardiac catheters and monitors are not MR compatible.
Nevertheless, a number of studies have demonstrated good agreement with recently
acquired invasive measurements using both methods.
Simpsons rule
Several studies have shown that MR1 is accurate and reproducible for estimation of both
left and right ventricular volumes in normal and abnormal subjects (119, 142-152), and is
probably superior to conventional echocardiography (153, 154). Some investigators did
experience difficulty outlining the right ventricle (151), and in pulmonary hypertension
intra- and inter-observer errors seem to be greater, in particular for the right ventricle.
Boxt et al reported a right to left ventricular stroke volume ratio of 3.17 to 1 due to
tricuspid regurgitation with reduced reproducibility of both left and right ventricular
measurements (120). Hoeper et al found that this method of calculating cardiac output
constantly overestimated the cardiac output for the same reason (155).
Blood flow
There has been more success with methods that derive cardiac output by measuring blood
flow through the aorta or main pulmonary artery. The use of MRI velocity mapping to
measure blood flow has been extensively validated in phantom, animal and human
subjects (see Chapter 7)(156-163). Tardivon et al reported a good correlation for right
cardiac output and stroke volume between MRI and cardiac catheterisation in PPH,
however agreement between the two was poor (127). Hoeper et al studied 16 patients
with primary or thromboembolic pulmonary hypertension and found good agreement for
right cardiac output between MRI and catheterisation in all but two subjects (155).
Mousseaux et al reported similar findings in a study of 19 subjects, 12 with primary or
secondary pulmonary hypertension and 4 post-cardiac transplant (164).
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1.6 Aims of research
As discussed, clinical and study endpoints have always focussed on changes in
pulmonary haemodynamics and exercise tolerance as a means ofmonitoring patients with
pulmonary hypertension. Our aim was to investigate an alternative strategy; studying the
adaptation response of the heart and pulmonary vasculature to pulmonary hypertension.
There have been surprisingly few published attempts to study the effects of treatment on
the morphology of the right heart and pulmonary circulation using echocardiography.
Barst found improvements in right ventricular function and interventricular septal
movement following calcium channel blockers and phenoxybenzamine (165). Rich and
Brundage reported a reduction in right ventricular chamber size and normalisation of the
systolic interventricular septal curvature in a small group of patients treated with calcium
channel blockers (19). Hinderliter et al also demonstrated less right ventricular dilatation
and improved septal curvature following twelve weeks of continuous intravenous
prostacyclin (29).
Modern advances in cross-sectional imaging, in particular Magnetic resonance imaging
(MRI), have made it possible to make anatomical and physiological measurements in the
cardiorespiratory system with a high degree of accuracy and reproducibility. We chose
MRI for this study, because the lack of radiation exposure and contrast injection makes it
more suitable for repeated studies than CT.
Anatomical measurements made with MRI are accurate and reproducible. Unlike
haemodynamic measurements they are not influenced by variation in short-term
physiological factors such as hydration status, posture, heart rate or oxygen saturation.
Therefore changes in these measurements may reflect the effect of sustained rises in
pulmonary artery pressure. In other words they may measure the response of the right
ventricle and pulmonary circulation to longstanding pulmonary vascular disease. If this is
the case, they may provide the pulmonary vascular physician with an accurate non¬
invasive means of monitoring disease progression and the response to treatment. An
analogy can be made with the use of glycosylated haemoglobin in monitoring patients
with diabetes, where the HbAlc provides an assessment of glucose level over the
previous few months (166). The rate of change of these variables may also provide useful
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prognostic information, and help with treatment decisions, in particular the difficult
decision of when to list for transplantation. MRI can also provide measurements of blood
flow in the pulmonary circulation quickly and accurately, which may also provide a
means ofmonitoring the "burden of disease" over time.
Our aim in this thesis was to develop indices that may be useful in this alternative
approach to the assessment of patients with pulmonary hypertension, derived from
anatomical and physiological measurements made with MRI. We then studied the
accuracy of these indices in detecting and quantifying pulmonary artery pressure at right
heart catheterisation, and any potential advantages over doppler echocardiography, the
current gold standard noninvasive investigation. Long term follow-up studies to test the




Patients were usually admitted to the Scottish Pulmonary Vascular Unit (SPVU) for
investigation or reassessment on a Monday and discharged on a Friday. One or two
patients were admitted every week and underwent a series of pre-booked investigations
(Table 2A) including right heart catheterisation on a Thursday. Management decisions
were made on a Friday before discharge.
Table 2A: Routine investigation at Scottish Pulmonary Vascular Unit







Human immunodeficiency virus serology
Hepatitis B and C serology
Arterial blood gases
Chest radiograph
High resolution CT scanning
Ventilation/Perfusion scanning or CT pulmonary angiography
Doppler echocardiography
Pulmonary function tests
Six minute walk test
Right heart catheterisation
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The study protocol is shown in Table 2B. Consent was sought shortly after admission.
MRI and doppler echocardiography (Echo) were performed as soon after right heart
catheterisation (RHC) as possible in those unable to follow the schedule for logistical or
personal reasons.




Wednesday Six minute walk test Magnetic resonance
imaging
Thursday Right heart catheterisation
Friday Analysis of data
2.2 Study subjects
2.2.1 Recruitment
This study was approved by West Glasgow Hospitals NHS Trust Ethics Committee. All
patients referred to the SPVU for investigation or reassessment of suspected pulmonary
hypertension between September 1999 and March 2001 were considered for enrolment.
Subjects who had previously been enrolled were not studied a second time.
Consent forms and Patient Information Sheets are reproduced in Appendix 1. It can be
seen that this was part of a larger study run by the SPVU comparing the data obtained
from ambulatory pulmonary artery monitoring, cardiopulmonary exercise testing and
magnetic resonance imaging. We have only submitted the MRI data in this thesis.
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2.2.2 Demographics
Twenty-eight subjects (nine male, nineteen female) were enrolled after informed consent
was obtained (Table 2C). All had normal left ventricular function and morphology at
echocardiography.
PAHT was confirmed in twenty-one subjects (Table 2C), of whom seven had PPH, five
connective tissue disease (CTD), three congenital heart disease (CHD), two chronic
obstructive pulmonary disease (COPD), two portopulmonary disease (PP), one chronic
thromboemboembolism (CTEPHT) and one hereditary haemorrhagic telangiectasia
(HHT). Seven subjects had normal pulmonary haemodynamics at RHC, and had been
referred because of evidence at Echo (subjects 4,6,11,12,25) or cardiopulmonary exercise
testing (subjects 14,23) coupled with a strong clinical suspicion ofPAHT.
2.3 Conventional assessment of pulmonary haemodynamics
2.3.1 Right heart catheterisation
2.3.1.1 Method
This was performed according to our standard protocols using a balloon-tipped,
thermodilution, cardiac catheter (Swan Ganz, 7-F, Baxter Healthcare, Irvine, CA, USA).
Pressures were recorded in the right atrium, right ventricle and proximal pulmonary
artery and an estimate of pulmonary artery occlusion pressure was made with the catheter
in the wedge position. Cardiac output was averaged over a minimum of three
measurements made by thermodilution except for those with shunting when the direct
Fick method was used (subjects 8,10,15). Measurements were made on supplementary
oxygen for those on long term oxygen therapy (subjects 16,17,20,21). Pulmonary
hypertension was defined as a MPAP of 25 mmHg or more (5).
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1 F 40 2.01 ppH« 52 3.4 * 58
2 M 42 1.67 PPH 63 3.3 14 144
3 M 51 1.68 CTD 40 3.5 8 64
4 F 53 1.61 No PAHT 16 5.7 11 49
5 F 56 1.51 PPH 61 3.7 7 112
6 F 32 1.61 No PAHT 19 5.1 8 < 25
7 F 50 1.98 CTEPHT 27 3.9 9 41
8 F 38 1.40 CHD 78 5.5 4 **
Eisenmengers VSD
9 M 29 2.00 PP 36 6.7 8 52
10 F 44 1.77 CHD 66 4.7 * 121
Eisenmengers ASD
11 F 54 1.72 No PAHT 15 6.0 7 36
12 F 42 1.51 No PAHT 19 4.1 10 16
13 F 58 1.82 PPHa 31 4.6 12 25
14 F 64 1.47 No PAHTp 16 4.4 6 27
15 F 33 1.63 CHD 78 6.2 9 74
Eisenmengers VSD
16 M 58 1.92 CTDPz 44 2.7 * 88
17 F 61 1.40 CTDX 34 2.8 4 100
18 M 62 1.95 PPHa 53 3.6 13 104
19 M 51 1.86 COPD 29 3.7 12 52
20 M 60 2.00 COPDPz 39 4.8 14 50
21 M 66 1.83 PPHX 40 2.6 7 74
22 F 31 1.92 PP 41 6.3 10 ***
23 F 48 1.83 No PAHT 16 3.4 11 23
24 F 68 1.75 CTD 35 5.4 12 58
25 F 60 1.97 No PAHT 16 6.8 7 38
26 F 57 1.59 HHT 53 6.4 6 52
27 F 43 1.94 CTD 38 4.6 5 64
28 M 59 1.66 PPH 47 3.7 2 52
FOOTNOTES:
BSA = Body surface area, MPAP = Mean pulmonary artery pressure, CO = Cardiac output, Echo
= Doppler echocardiography, PASP = pulmonary artery systolic pressure, PAHT = Pulmonary
arterial hypertension, PAOP = pulmonary artery occlusion pressure, PPH = Primary pulmonary
hypertension, CTD = Connective tissue disease, CTEPHT = Chronic thromboembolic pulmonary
hypertension, CHD = Congenital heart disease, PP = Portopulmonary hypertension, HHT =
Hereditary haemorrhagic telangiectasia. a = Systemic hypertension, p = Ischaemic heart disease,
z = Long term oxygen therapy * = PAOP unobtainable, ** = High pressure but unquantifiable, ***
= No tricuspid regurgitation so unable to estimate pressure
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2.3.1.2 Results
Measurements were successfully obtained in all twenty-eight subjects and the results are
shown in Table 2C. There was a wide range of MPAP (15-78 mmHg) and CO (2.6-6.8
L/min) and statistically significant differences between normal subjects and those with
raised pulmonary artery pressure for all variables (Table 2D). PAOP was normal (ie:<15
mmHg) in all subjects except 1, 10 and 16 in whom it could not be measured for
technical reasons. There were no major complications.
Table 2D: Comparison : Normals vs PAHT
NORMALS (n=7) PAHT (n=21)
Mean Range Mean Range p-value
AGE (yrs) 50+11 32-64 50 ± 12 29-68 NS
BSA 1.67 ±0.18 1.47-1.97 1.78 ±0.2 1.4-2.01 NS
MPAP (mmHg) 17 ±2 15-19 47 ± 15 27-78 < 0.0001
CO (L/min) 5.1 ±1.2 3.4-6.8 4.4 ±1.3 2.6-6.7 NS
PASP (Echo) 31 ±11 16-49 73 ±31 25-144 < 0.0001
(mmHg)
FOOTNOTES:
BSA = Body surface area, MPAP = Mean pulmonary artery pressure, CO = Cardiac output, Echo
= Doppler echocardiography, PASP = pulmonary artery systolic pressure, PAHT = Pulmonary
arterial hypertension, NS = not significant
2.3.1.3 Discussion
Our subject group and cardiac catheterisation results are similar to those reported by




Pulmonary artery systolic pressure (PASP) was estimated from tricuspid regurgitation in
the conventional way (Acuson Sequoia c256, Mountain View, CA, USA) as described in
the Introduction. Standard assessments of cardiac chamber size, valvular competence and
right and left ventricular function were also made. All measurements were made by the
same experienced echocardiographer who was not aware of the results of cardiac
catheterisation. Measurements were made on supplementary oxygen for those on long
term oxygen therapy.
The senior echocardiographer, who performed all of the measurements included in this
thesis, reported PASP without correcting for estimated right atrial pressure. We chose to
define pulmonary hypertension as a PASP of > 35mmHg, which corresponds with a
tricuspid regurgitation jet velocity of > 3.0 m/s assuming right atrial pressure to be zero.
This is the definition suggested by Yock and Pop when they first described this method
(65), however, there has been disagreement on the correct definition in the literature since
then, with many authors choosing to define pulmonary hypertension as a PASP of > 40
mmHg. Unfortunately it is often unclear whether this includes right atrial pressure,
making direct comparison difficult. Ideally, actual measurements of tricuspid
regurgitation jet velocity should be reported, to remove any ambiguity, however this has
not been the case historically. In any case, this would have no effect on most of the
correlations reported in this thesis.
All twenty-eight subjects underwent doppler echocardiography within two days of
cardiac catheterisation except 27 and 28 in whom the interval was four weeks. The values
for estimated PASP are shown in Table 2C and ranged from 16 to 144 mmHg. Values are
listed for twenty-five subjects; subject 6 was reported as " < 25 " and a value of 25 was
used for statistical analysis. In subject 8, estimated PASP was raised but could not be
2.3.2.2 Results
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accurately measured, and was therefore not included in linear regression analysis. PASP
could not be measured in subject 22.
There was a significant difference between the normal subjects and those with pulmonary
hypertension (p < 0.0001 Table 2D) and a good correlation with MPAP as shown in
Figure 2A (r = 0.76). However there were three false positive results (subjects 4,11 and
25), one failed scan (subject 22) and one false negative result (subject 13), giving an
overall sensitivity of 90% and a specificity of 57%.
2.3.2.3 Discussion
Our results are broadly in line with the published literature regarding the accuracy and
limitations of doppler echocardiography for the estimation of pulmonary artery pressure.
Similar correlations have been reported in several studies (74). Our failure rate was lower
than previously reported; in particular both of our subjects with COPD were successfully
scanned (78, 87). There have been reports of both false positive and false negatives,
although it should be noted that all our normal subjects had been referred with a high
index of clinical suspicion of pulmonary vascular disease, five with an abnormal
echocardiogram.
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RHC = right heart catheterisation, Echo = doppler echocardiography, MPAP = mean
pulmonary artery pressure, PASP = pulmonary artery systolic pressure, CI = confidence intervals,
PI = prediction intervals
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2.4 Magnetic resonance imaging
2.4.1 General protocol
MRI scans were performed using a standard scanner (Impact Expert 1.0 T, Siemens
Medical Engineering, Erlangen, Germany, see Figure 2B). Imaging sequences broadly
followed the protocol described by Marcus et al (118). A coronal section was performed
through the chest and from this "scout" sequence a horizontal cross-sectional view was
obtained through the base of the heart showing the main pulmonary artery and
descending aorta. From this image we obtained a series of cross-sectional images from
the bifurcation of the main pulmonary artery to the right ventricular outflow tract at ten
millimetre intervals (Figure 2C, Sequence A). Image acquisition was triggered by the
ECG R wave resulting in a stack of images at each slice position. Main parameters were
T1 weighted SE with TR approximately 700ms, TE 30, slice thickness 10 mm, Flip
Angle 90 degrees. To optimise scan time each slice was acquired at a different point in
the cardiac cycle using an interleaved 45ms interval. From the initial coronal "scout"
sequence a horizontal long-axis view was then obtained showing the four chambers of the
heart. A series of short-axis images were then acquired perpendicular to the long-axis
view, starting at the tricuspid valve and covering the complete right ventricle from base
to apex (Figure 2C, Sequence B). Finally the initial coronal "scout" sequence was used to
find the long axis of the right pulmonary artery as it passes beneath the arch of the aorta
with a series of cross-sectional and coronal images to confirm the position of the vessel
(see Chapter 7 Figures 7A-7C). An oblique sagittal image was then used to perform a
flow quantification in the right pulmonary artery. This was repeated after exercise in
selected subjects (see Chapter 8).
Short-axis image acquisition was triggered by the ECG R wave and performed in cine
mode with a temporal resolution of 55 milliseconds, resulting in a series of images during
the cardiac cycle at 55 ms intervals at each slice position. This was done by a segmented
Flash with view-sharing to allow a reduced time resolution. Main parameters were TR
110, TE 6.1, slice thickness 10 mm, Flip Angle 20 degrees.
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Figure 2B: Magnetic resonance imaging
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Figure 2C: MRI scanning protocol
RA = right atrium, LA = left atrium, RV = right ventricle, LV = left ventricle, MPA = main
pulmonary artery, A = aorta, RPA = right pulmonary artery, LPA = left pulmonary artery
73
Fifteen consecutive heartbeats were required to acquire a set of images in each plane.
Subjects were instructed to hold their breath during the acquisition of short-axis images
of the ventricles. This resulted in a 12 to 15 second breathhold for image acquisition in
each short-axis slice position and six to eight slices were required per patient. Subjects
were instructed to breathhold at end-expiration because breathholding at deep inspiration
has been reported to diminish cardiac output by up to 40% in normal subjects (167-169).
A flow quantification was performed in the right pulmonary artery at rest in all subjects
and after exercise in a proportion. The method is described later in the relevant chapters
(sections 7.2 and 8.2). Studies were performed without supplementary oxygen for
logistical reasons.
2.4.2 Study subjects
Twenty-two out of twenty-eight subjects underwent MRI within two days of RHC. The
remaining six were scanned up to two weeks later (subjects 1,2,6,15,19 and 21). Scanning
was incomplete in one subject who was unable to breathhold adequately and has since
died (subject 16), and was abandoned in another subject due to acute claustrophobia
(subject 7).
2.4.3 Image analysis
The following measurements were made: Right and Left Ventricular Mass (RVM, LVM,
see Chapter 3), Right and Left ventricular end-diastolic volume (RVEDV, LVEDV, see
Chapter 4), Right Ventricular End-Diastolic Wall Thickness (RVWT) and Left
ventricular posterior wall thickness (LVPWT, see Chapter 5), Main Pulmonary Artery
diameter (MPAD) and diameter of descending Aorta (AOD, see Chapter 6), Mean and
Peak velocity in the right pulmonary artery (MV, PV, see Chapters 7 and 8). The
calculation of each measurement is described in the relevant chapter. The raw data is
tabulated in Appendix 2.
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The first image acquired after R wave triggering was considered to best represent end-
diastole and used to calculate RVM, LVM, RVEDV, LVEDV, RVWT and LVPWT. The
cross-sectional images used to measure MPAD and AOD were not ECG gated.
2.5 Statistical analysis
Data was analysed using Minitab for Windows (Release 12.1). Pearson's correlation
coefficient and linear regression analysis were used to assess the relationship between
MPAP measured at RHC and measurements made at Echo and MRI. Where appropriate,
subjects were also divided into those with normal MPAP at RHC (Normals) and those
with raised MPAP (PAHT). The 2 sample t test was used to assess the significance of
differences between the two groups. An "intention to scan" analysis was done when




As discussed earlier, a linear relationship between right ventricular mass and MPAP has
been described in PPH but not for other forms of PAHT (122). In our first study we
investigated whether a new Ventricular Mass Index measured with MRI and not
previously described in PAHT can provide an accurate means of estimating MPAP non-
invasively in subjects with both PPH and a wide range of types of secondary PAHT
undergoing routine invasive RHC. We then compared the accuracy of these estimates
with those made at Echo.
3.2 Method
3.2.1 Study subjects
Subjects were recruited as outlined in Chapter 2 and are shown in Table 2C. Subjects 27
and 28 were not included in this study because the interval between RHC and Echo of
four weeks was considered to be too long to make an accurate comparison.
3.2.2 MRI image analysis
RVM and LVM were calculated using a modified Simpsons rule as follows (118, 122):
The interventricular septum was taken to be part of the left ventricle. The cross-sectional
area of right ventricular myocardium in each end-diastolic short-axis slice was calculated
by manually tracing around the interior and exterior of the right ventricular free wall (see
Figure 3A). The total volume of muscle for that slice was then obtained by multiplying
the cross-sectional area by the slice thickness. This process was repeated for each short-
axis slice and the total volume of right ventricular myocardium calculated by summing
all the slice volumes (Figure IE). RVM was then derived by multiplying the total volume
by the specific density of cardiac muscle (1.05g/cm ). The moderator band was included
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Figure 3A: Short-axis images of ventricles
used to calculate RVM and LVM
NORMAL PAHT
RVM = right ventricular mass, LVM = left ventricular mass,
ACW = anterior chest wall, RV = right ventricle, LV = left ventricle
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in the calculation for RVM where it appeared. The process described above was repeated
for the left ventricle to calculate LVM except that the cross-sectional area of myocardium
in each slice was calculated by subtracting the area of the internal polygon from the
external (see Figure 3A). Our new Ventricular Mass Index (VMI) was obtained by
dividing RVM by LVM to correct for variation in body habitus, a technique used in
animal models of pulmonary hypertension (170), but not previously used in man. A
further ventricular mass index was obtained by dividing RVM by BSA, as described by
Katz et al (122).
3.2.3 Statistical analysis
Data was analysed using Minitab for Windows (Release 12.1). Pearson's correlation
coefficient and linear regression analysis were used to assess the relationship between
MPAP measured at RHC and measurements made at Echo and MRI. Where appropriate,
subjects were also divided into those with normal MPAP at RHC (Normals) and those
with raised MPAP (PAHT). The two sample t test was used to assess the significance of
differences between the two groups. An "intention to scan" analysis was done when
calculating sensitivities and specificities.
3.3 Results
3.3.1 Ventricular mass
The mean calculated values for RVM, LVM and VMI are shown in Table 3A for twenty-
four subjects. Measurements were not possible in subject 16 due to difficulty breath-
holding and subject 7 due to claustrophobia. There was a significant difference between
the two groups for RVM (p<0.005) and VMI (p<0.01), but not for LVM. There was a
weak correlation between MPAP and RVM (r = 0.56, Figure 3B), which improved after
correcting for BSA (r = 0.65, Figure 3C) but a much stronger correlation with reduced
scatter between MPAP and VMI, (r = 0.81, Figure 3D). If we take a VMI of > 0.6 as
abnormal there was one false negative result (subject 24) and two false positives (subjects
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4,25) with two scanning failures (subjects 7,16), giving a sensitivity of 84% and a
specificity of 71% (Table 3B).
Table 3A: Comparison : Normals vs PAHT
NORMALS (n=7) PAHT (n=19)
Mean Range Mean Range p-value
AGE (yrs) 50 ±11 32-64 50 :± 12 29-68 NS
MPAP (mmHg) 17 ±2 15-19 47 ± 16 27-78 < 0.0001
CO (L/min) 5.1 ±1.2 3.4-6.8 4.4 ± 1.3 2.6-6.7 NS
RVM (g) 66 +24 31-107 126 ±36 63-174 < 0.005
LVM (g) 129 ±24 98-172 145 ±41 81-205 NS
VMI 0.5 ±0.2 0.2-0.7 0.9 ±0.2 0.6-1.4 < 0.01
Echo PASP 31 ±11 16-49 75 ±33 25-144 < 0.0001
(mmHg)
FOOTNOTES:
BSA = Body surface area, MPAP = Mean pulmonary artery pressure, CO = Cardiac output, Echo
= Doppler echocardiography, PASP = pulmonary artery systolic pressure, PAHT = Pulmonary
arterial hypertension, NS = not significant, RVM = right ventricular mass, LVM = left ventricular
mass, VMI = ventricular mass index








VMI (n = 26) r= 0.81 84 % 71 %
Echo PASP (n = 26) r = 0.77 89 % 57 %
(mmHg)
FOOTNOTES:
MPAP = mean pulmonary artery pressure, PAHT = pulmonary arterial hypertension, VMI =
ventricular mass index, Echo = doppler echocardiography, PASP = pulmonary artery systolic
pressure
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Figure 3B: Correlation between MPAP and RVM
MPAP = mean pulmonary artery pressure, RVM = right ventricular mass,
CI = confidence intervals, PI = prediction intervals
80








30 40 50 60 70 80
RVM/BSA
MPAP = mean pulmonary artery pressure, RVM = right ventricular mass,
BSA = body surface area, CI = confidence intervals, PI = prediction intervals
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Figure 3D: Correlation between MPAP and VMI
MPAP = mean pulmonary artery pressure, VMI = ventricular mass index,
CI = confidence intervals, PI = prediction intervals
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3.3.2 Doppler echocardiography
The values for estimated PASP are shown in Table 2C and statistical analysis in Tables
3A and 3B. Values are listed for twenty-four subjects; subject 6 was reported as " < 25 "
and a value of 25 was used for statistical analysis. In subject 8, estimated PASP was
raised but could not be accurately measured, and was therefore not included in linear
regression analysis. PASP could not be measured in subject 22. There was a significant
difference between the two groups (p < 0.0001) and a good correlation with MPAP as
shown in Figure 3E (r = 0.77) and Table 3B. However there were three false positive
results (subjects 4,11 and 25), one failed scan (subject 22) and one false negative result
(subject 13), giving an overall sensitivity of 89% and a specificity of 57% (Table 3B).
3.4 Discussion
Our Ventricular Mass Index measured with Magnetic Resonance Imaging is a new
clinical tool that provides an accurate and practical means of estimating mean pulmonary
artery pressure non-invasively in subjects with Primary and Secondary pulmonary arterial
hypertension with a wide range of pressures and diagnoses. Ventricular Mass Index
correlated well with mean pulmonary artery pressure at right heart catheterisation, and
although confidence and prediction intervals are relatively wide indicating limited
precision, they are narrower than for echocardiography in the same group of subjects.
The method we used for indexing Right Ventricular Mass has not been previously
described in pulmonary hypertension. We found a closer agreement for our Ventricular
Mass Index than for the method reported by Katz et al who devised a Right Ventricular
Mass index calculated by dividing Right Ventricular Mass by Body Surface Area in a
study of eight adults and five children with Primary Pulmonary Hypertension (122). We
have also shown that our Ventricular Mass Index may be more specific for pulmonary
arterial hypertension than Doppler Echocardiography, the current gold standard non¬
invasive investigation. This may be because pulmonary hypertension also has an effect
on the morphology of the left ventricle (see Chapter 4). Ventricular Mass Index was also
more
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Figure 3E: Correlation between MPAP and Echo
MPAP =
PASP =
mean pulmonary artery pressure, Echo = doppler echocardiography,
pulmonary artery systolic pressure, CI = confidence intervals, PI = prediction intervals
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sensitive than Doppler Echocardiography in those patients in whom scanning was
successfully completed (94% versus 89% excluding subjects 7,16). This is the first study
to suggest a practical advantage of magnetic resonance imaging over Doppler
Echocardiography in the routine assessment of pulmonary haemodynamics. The reason
for this may be that Ventricular Mass Index reflects the right ventricular response to a
given pulmonary artery pressure sustained over a long period. It is therefore unlikely to
be influenced by short-term physiological variables such as heart rate, posture, hydration
status or supplementary oxygen, all of which may affect the real-time pressure estimates
made by Doppler Echocardiography. Although Doppler Echocardiography is a relatively
cheap and practical method of detecting acute disease and assessing acute changes in
pulmonary haemodynamics following an intervention such as exercise, Magnetic
Resonance Imaging is more likely to provide a reliable assessment of long-term disease
progression and response to treatment. This is because ventricular mass is unlikely to
respond to transient changes in pulmonary artery pressure.
Magnetic Resonance Imaging does have limitations but was well tolerated by almost all
our subjects. The problems of noise, claustrophobia and prolonged breath-holding are fast
diminishing with advancing technology. The presence of unsecured ferromagnetic
material in the body remains a contraindication. Many patients with pulmonary
hypertension are treated with continuous intravenous or subcutaneous prostanoids
requiring a syringe pump, which would have to remain outside the scanning room.
There are several possible sources of error in this study. No attempt was made to blind
the reporting of scans which may have led to bias and we did not test interobserver
reproducibility. Some difficulty was encountered in delineating the right ventricular
lumen due to the presence of papillary muscles, in particular at the apex of the ventricle,
but this was minimised by adjusting the contrast appropriately. This may have led to a
tendency to overestimate right ventricular mass. All our values for left ventricular mass
fall within the normal ranges suggested recently by Lorenz et al (119), however only
three of our seven subjects without pulmonary hypertension at rest fall within the
suggested normal range for right ventricular mass. This may suggest overestimation of
right ventricular mass in our study, however we found a similar range of values to Katz et
al (122). It should also be remembered that all our "normal" subjects were initially
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referred with clinical evidence of pulmonary vascular disease. Since short axis sections
for both ventricles were taken perpendicular to the long axis of the left ventricle, this
could have led to oblique sections being taken through the right ventricle and
inaccuracies in slice volume estimation. Seven of our subjects had ischaemic heart
disease or systemic hypertension, possibly altering left ventricular mass and consequently
Ventricular Mass Index. However there was no evidence of left ventricular dysfunction
or hypertrophy at echocardiography and right heart catheterisation. Although subjects
16,17, 20 and 21 only received supplementary oxygen during Doppler Echocardiography
and right heart catheterisation, and not during Magnetic Resonance Imaging, this is
unlikely to have affected our anatomical measurements.
We have shown that Magnetic Resonance Imaging may be more accurate than Doppler
Echocardiography, with similar or better sensitivity and specificity for both primary and
secondary forms of the disease. Although Doppler Echocardiography was successfully
performed in almost all subjects in this study, there is known to be a failure rate as high
as 60% in some patient groups due to body habitus, the absence of a tricuspid regurgitant
jet or co-existing lung disease (78). These are not limiting factors for Magnetic
Resonance Imaging which may provide a useful alternative for monitoring patients and
screening high risk individuals in whom Doppler Echocardiography is unhelpful. Indeed,
with wider availability, reduced costs and the advent ofmodern scanners it could become




Prognosis in pulmonary hypertension (PAHT) depends upon the functional integrity of
the right ventricle. Death is commonly due to progressive right heart failure or
arrhythmias, however it is unknown why some patients maintain cardiac function while
others develop right heart failure in the face of similar pulmonary haemodynamics.
Although left ventricular function is compromised (120, 171), the role of the left ventricle
in this process is incompletely understood.
The cardiac ventricles are known to respond to sustained rises in afterload by two
mechanisms: hypertrophy and dilatation. The former is characterised by raised
ventricular mass and the latter by enlarged ventricular volumes. A number ofMRI studies
have shown that both right ventricular mass (RVM) and right ventricular end-diastolic
volume (RVEDV) are raised in PAHT (120, 122, 155, 171, 172), but the factors that
determine the extent to which this occurs are unclear. The rise in RVM has been shown
to correlate with mean pulmonary artery pressure (MPAP) (122, 172), however a
ventricular mass index derived by dividing right by LVM predicts MPAP more
accurately than an index derived by dividing by body surface area (BSA) (see Chapter 3)
(172). This suggests that left ventricular morphology may also be a factor in determining
how the right ventricle responds to pulmonary hypertension, but there have been no
published reports of this. Noordegraf et al showed that left ventricular ejection fraction
and wall thickness correlated well with right ventricular wall thickness in ten patients
with severe emphysema but did not measure pulmonary artery pressure (173). Cardiac
output (CO) does not seem to influence RVM (155).
Although the extent of right ventricular dilatation varies widely, there have been no
studies showing a relationship between RVEDV and the severity of pulmonary
haemodynamics. Boxt et al reported raised RVEDV and reduced left ventricular end-
diastolic volume (LVEDV) in eleven patients with primary pulmonary hypertension
(PPH) compared to a control group, and proposed that early diastolic paradoxical
movement of the left ventricular septum leads to impaired left ventricular filling and
87
reduced left ventricular stroke volume (120). Marcus et al demonstrated a negative
correlation between LVEDV and MPAP in twelve patients with PPH, but did not report a
relationship with RVEDV (171). Hoeper et al found no difference in right ventricular
volumes between those with a low and a normal CO, although tricuspid regurgitation was
more severe in those with a low CO (155).
In this study we used MRI to study the relationship between right ventricular mass and
volume, pulmonary haemodynamics and left ventricular mass and volume in patients
with a wide range of types of PAHT, in order to better understand the factors that govern
right ventricular hypertrophy and dilatation.
4.2 Method
4.2.1 Study subjects
Subjects were recruited as outlined in Chapter 2 and are shown in Table 2C. Twenty-one
subjects with pulmonary hypertension were enrolled after informed consent was
obtained, however only the sixteen subjects in whom adequate data was obtained were
included in the analysis (MPAP 49.6 +/- 15.5 mmHg, CO 4.6 +/- 1.4 L/min). Of these,
six had PPH, four connective tissue disease (CTD), three congenital heart disease (CHD),
two portopulmonary disease (PP) and one hereditary haemorrhagic telangiectasia (HHT).
Images could not be analysed in subjects 16, 18, 19 and 20 due to poor ECG gating, and
scanning failed in subject 7 due to acute claustrophobia.
4.2.2 MRI image analysis
MRI scans were performed using a standard scanner (Impact Expert 1.0 T, Siemens
Medical Engineering, Erlangen, Germany). Imaging sequences broadly followed the
protocol described by Marcus et al (118). Measurements were thought unlikely to be
affected by fluctuations in oxygen saturation, and therefore, because of logistical
difficulties in supplying oxygen, MRI studies were performed without supplementary
oxygen.
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RVM and LVM were calculated as described previously (see Chapter 3). RVEDV and
LVEDV were calculated as follows: The cross-sectional area of the ventricular lumen in
each end-diastolic short-axis slice (Figure 3A) was calculated by manually tracing around
the interior margin of the ventricle. The software then calculated the right and left
ventricular end-diastolic volume using the same principle as for mass (Chapter 3).
4.2.3 Statistical Analysis
Data was analysed using Minitab for Windows (Release 12.1). Pearson's correlation
coefficient and linear regression analysis were used to assess the relationship between
variables.
4.3 Results
LVEDV was not obtained in subject 9 due to technical failure. This measurement
correlated inversely with MPAP (r = 0.66) as has been previously reported (171) but
there were no other significant correlations between pulmonary haemodynamics and
RVM, RVEDV, LVM and LVEDV (Table 4A). However RVEDV correlated closely
with LVM (r = 0.83, Figure 4A) even after correcting for BSA (r = 0.78, Figure 4B), and
RVM correlated with LVM (r = 0.53, Figure 4C), even after correction for BSA (r = 0.54,
Figure 4D).
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Table 4A: Ventricular volumes and masses with correlations to BSA and
pulmonary haemodynamics. Correlations after correction for





RVEDV 112.0 ±31 57.1-155.0 0.59 -0.39 (-0.28) 0.00 (-0.08)
(mis)
RVM 121.0 ±34 62.6-173.9 0.12 0.21 (0.37) -0.21 (-0.24)
(g)
LVEDV 73.5 ±16 51.1-109.1 0.64 -0.66 (-0.63) 0.26 (0.31)
(mis)
LVM 140.0 ±38 80.5-205.0 0.47 -0.38 (-0.24) 0.17 (0.11)
M
FOOTNOTES:
RVEDV = Right ventricular end-diastolic volume, LVEDV = Left ventricular end-diastolic volume,
RVM = Right ventricular mass, LVM = Left ventricular mass, BSA = body surface area, MPAP =
mean pulmonary artery pressure, CO = Cardiac output, SD = standard deviation
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RVEDV = right ventricular end-diastolic volume, LVM = left ventricular mass,








Figure 4B: Correlation between RVEDV/BSA
and LVM/BSA
RVEDV = right ventricular end-diastolic volume, LVM = left ventricular mass,
BSA = body surface area, CI = confidence intervals, PI = prediction intervals
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RVM = right ventricular mass, LVM = left ventricular mass, CI = confidence intervals,
PI = prediction intervals
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Figure 4D: Correlation between RVM/BSA
and LVM/BSA
RVM = right ventricular mass, LVM = left ventricular mass, BSA = body surface area,
CI = confidence intervals, PI = prediction intervals
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4.4 Discussion
In this study, left ventricular mass was more important than pulmonary haemodynamics
in determining the right ventricular response to pulmonary hypertension. Right
ventricular mass and right ventricular end-diastolic volume correlated closely with left
ventricular mass even after correction for body surface area. There was no correlation
between left ventricular mass and pulmonary haemodynamics. This observation has not
been previously reported and may help us to understand why patients with similar disease
severity display widely differing degrees of right ventricular failure and hypertrophy.
There are two possible explanations for this. A feature of severe pulmonary hypertension
is paradoxical interventricular septal motion, or leftward septal bowing, suggested by
Boxt et al as a cause of impaired left ventricular filling (120). Increased left ventricular
mass is likely to result in reduced ventricular compliance. This may provide a survival
advantage by splinting the left ventricular cavity and limiting collapse of the left ventricle
during diastole, allowing the heart to tolerate greater degrees of right ventricular
hypertrophy and dilatation. Patients with smaller left ventricular muscle mass may die
earlier in the course of the disease. This may also explain the observed association
between pulmonary hypertension and systemic hypertension (174), since the resultant left
ventricular hypertrophy may be protective. A second possibility is that the left ventricle
may hypertrophy in response to recurrent encroachment by the right ventricle and
persistently low cardiac output, or some other mechanical or endocrine stimulus. This is
consistent with earlier studies that have clearly shown that left ventricular hypertrophy
occurs in animal models of pulmonary hypertension (175, 176). Laks et al suggested that
the ventricles may behave as a single structure and that sustained overload of one could
result in hypertrophy and dilatation of both (175). Our values for left ventricular mass fall
within the normal ranges recently suggested by Lorenz et al (119), although values for
three female subjects were more than one standard deviation above the mean. Two
subjects had controlled systemic hypertension (subjects 1 and 8) and one ischaemic heart
disease (subject 16), but there was no clear evidence of left ventricular hypertrophy or
dysfunction at echocardiography or right heart catheterisation in any of these patients.
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In healthy individuals, there is a linear relationship between body surface area and right
ventricular mass and end-diastolic volume (119). We expected this relationship to be
overwhelmed in pulmonary hypertension, with right ventricular parameters being dictated
primarily by pulmonary haemodynamics. This was indeed the case in our study for mass,
but not for volume. For similar reasons, we did not expect to find such a strong
relationship between right and left ventricular mass. We also expected right ventricular
mass, and perhaps end-diastolic volume, to correlate with the severity of disordered
pulmonary haemodynamics, but this was not the case for either in our study. Some
studies (122) have reported a correlation between right ventricular mass and mean
pulmonary artery pressure whereas others did not find one (155). There have been no
studies relating right ventricular end-diastolic volume to pulmonary haemodynamics.
Boxt et al did not report any correlations in a study of eleven patients with primary
pulmonary hypertension (120). Hoeper et al found no difference in right ventricular end-
diastolic volume and mass between two groups of patients with "normal" and "low"
cardiac outputs (155).
It is becoming clear that a number of additional factors are involved in the right
ventricular response to pulmonary hypertension. The extent of right ventricular dilatation
appears to depend upon left ventricular mass and body surface area. The extent of right
ventricular hypertrophy appears to depend upon both mean pulmonary artery pressure
and left ventricular mass, which may explain the accuracy of a ventricular mass index
derived by dividing right ventricular mass by left ventricular mass at predicting mean
pulmonary artery pressure (172).
This study was limited by the fact that all of our subjects were known to have abnormal
right ventricular function and morphology at echocardiography, with the exception of
subject 22 who was diagnosed at elective right heart catheterisation during liver
transplantation. This is inevitable since the vast majority of patients are picked up on the
basis of abnormalities at echocardiography. Unfortunately this deprives us of the chance
to study patients in the early stages of disease, before the right ventricle becomes
abnormal. Earlier detection of disease is needed to make these important studies possible.
There are a number of potential sources of error in our study. No attempt was made to
blind the reporting of scans which may have led to bias and we did not test interobserver
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reproducibility. Since short axis sections for both ventricles were taken perpendicular to
the long axis of the left ventricle, this could have led to oblique sections being taken
through the right ventricle and inaccuracies in slice volume estimation. Some difficulty
was encountered in delineating the right ventricular lumen due to the presence of
papillary muscles, in particular at the apex of the ventricle, but this was minimised by
adjusting the contrast appropriately. This may have led to a tendency to overestimate
right ventricular mass and underestimate right ventricular end-diastolic volume, however
previous studies have reported similar values for mass (122) and volume (120) in
pulmonary hypertension. Furthermore, any error is likely to be systematic and should not
affect correlations between variables. Although subjects 17 and 21 only received
supplementary oxygen during right heart catheterisation, and not during Magnetic
Resonance Imaging, this is unlikely to have affected our anatomical measurements.
In summary, this study has shown that increased left ventricular mass correlates better
with right ventricular hypertrophy and dilatation than pulmonary haemodynamics. This
may be because increased left ventricular mass leads to reduced compliance and splinting
of the left ventricle. This in turn may provide a survival advantage by preventing the
impaired left ventricular filling seen in severe pulmonary hypertension. Alternatively,
right ventricular overload may result in left ventricular hypertrophy.
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5 Ventricular wall thickness
5.1 Introduction
Pulmonary hypertension is characterised by right ventricular dilatation and hypertrophy.
The increase in right ventricular mass correlates well with the rise in pulmonary artery
pressure, especially after correcting for body habitus (122, 172). Although this can be
used to detect and quantify pulmonary hypertension (see Chapter 3), it is time consuming
and cumbersome. A number of investigators have proposed measuring right ventricular
wall thickness (RVWT) instead, and several echocardiographic and MRI studies have
been published using a variety of approaches. Subxiphoid echocardiography has been
used to quantify right ventricular hypertrophy (177) and a correlation has been reported
with MPAP and total pulmonary resistance in thirty-three subjects with sarcoidosis (178).
Tsuda et al used three different echocardiographic approaches to study twenty-one
subjects with right ventricular overload due to a variety of congenital and acquired
cardiac disorders and found a good correlation with systolic PAP (179).
MRI has three important advantages over echocardiography in measuring RVWT. Firstly,
it can provide cross-sectional images in any plane allowing measurements to be made at
right angles to the ventricular wall. Secondly, these measurements can be made in several
places if required, and thirdly it gives superb discrimination between blood, fat and
muscle and anatomical measurements are accurate and reproducible (see Chapter 3). In
1985, Longmore et al reported close agreement between direct and MRI measurements of
right ventricular wall thickness in a study using a porcine heart model (180). Since then, a
number of studies have shown increased RVWT to be a marker of raised PAP (123, 125,
136, 181, 182). Three of these studies reported correlations with MPAP, two using
measurements of the right ventricular free wall (125, 136) and the third using
measurements in the right ventricular outflow tract (123). In addition, an attempt was
made to correct for body habitus by some investigators using body surface area (BSA)
(125) or LVPWT (136) but not in others. There have been no studies comparing the
accuracy of RVWT and doppler echocardiography in predicting pulmonary artery
pressure.
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The purpose of this study was to see if a single simple MRI measurement of RVWT
would accurately predict MPAP at routine cardiac catheterisation in subjects referred for
investigation or reassessment of pulmonary hypertension. We then made a comparison
with doppler echocardiography, the current non-invasive gold standard.
5.2 Method
5.2.1 Study subjects
Subjects were recruited as outlined in Chapter 2 and are shown in Table 2C. Subjects 27
and 28 were not included in this study because the interval between RHC and Echo of
four weeks was considered to be too long to make an accurate comparison.
5.2.2 MRI image analysis
RVWT was defined as the thickest part of the right ventricular free wall measured in
millimetres between base and apex seen on the end-diastolic four-chamber long-axis
view (Figure 5A). Similarly, LVPWT was defined as the thickest part of the free left
ventricular wall on the same image. LVM was calculated using the method described in
Chapter 3.
Three forms of RVWT index were calculated by dividing RVWT by BSA, LVPWT and
LVM in turn.
5.2.3 Statistical analysis
Data was analysed using Minitab for Windows (Release 12.1). Pearson's correlation
coefficient and linear regression analysis were used to assess the relationship between
MPAP measured at RHC and measurements made at Echo and MRI. Subjects were also
divided into those with normal MPAP at RHC (Normals) and those with raised MPAP
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Figure 5A: Four chamber images used to
measure RVWT and LVPWT
NORMAL PAHT
RVWT (thickest point of right
ventricular anterior free wall)
LVPWT (thickest point of left
ventricular posterior free wall)
RVWT = right ventricular wall thickness, LVPWT = left ventricular posterior wall thickness,
ACW = anterior chest wall, RA = right atrium, RV = right ventricle, LV = left ventricle,
AR = aortic root
ACW
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(PAHT). The 2 sample t test was used to assess the significance of differences between
the two groups. An "intention to scan" analysis was done when calculating sensitivities
and specificities.
5.3 Results
5.3.1 RVWT, LVPWT and LVM
RVWT was successfully measured in twenty-five subjects, LVPWT in twenty-three and
LVM in twenty-four. Scanning was incomplete in subject 7 due to claustrophobia and
subjects 16 and 18 due to breathlessness. There was a significant difference between the
two groups for RVWT (p<0.0001) but not for LVPWT or LVM (Table 5A). There was
also a close correlation between RVWT and MPAP (r = 0.83, Figure 5B). If we take a
RVWT of 8 millimetres as abnormal then there is one false negative and no false
positives and one failed scan giving a sensitivity of 89% and a specificity of 100% (Table
5B).
5.3.2 RVWT indices
All three indices of RVWT successfully distinguished between the Normal and PAHT
groups (Table 5A), however none improved correlation or accuracy. Indexing with BSA
yielded a similar correlation with the same degree of scatter (Figure 5C). Accuracy
actually deteriorated after indexing with LVPWT and LVM with the majority of points
on the graph lying to one side and the apparently good correlations dependent upon a few
outlying points (Figures 5D and 5E).
5.3.3 Doppler Echocardiography
The values for estimated PASP are shown in Table 3A and statistical analysis in Tables
5A and 5B. Values are listed for twenty-four subjects; subject 6 was reported as " < 25 "
and a value of 25 was used for statistical analysis. In subject 8, estimated PASP was
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raised but could not be accurately measured, and was therefore not included in linear
regression analysis. PASP could not be measured in subject 22. There was a significant
difference between the two groups (p < 0.0001) and a good correlation with MPAP as
shown in Figure 3E (r = 0.77). However there were three false positive results (subjects
4,11 and 25), one failed scan (subject 22) and one false negative result (subject 13),
giving an overall sensitivity of 89% and a specificity of 57% (Table 5B).
Table 5A: Comparison : Normals vs PAHT
NORMALS (n=7) PAHT (n=19)
Mean ±SD Range Mean ±SD Range p-value
AGE (yrs) 50 ±11 32-64 50 ± 12 29-68 NS
MPAP (mmHg) 17 ±2 15-19 47 ± 16 27-78 < 0.0001
CO (L/min) 5.1 ± 1.2 3.4-6.8 4.4 ± 1.3 2.6-6.7 NS
RVWT (mm) 6 ±2 4-9 13 ±4 6-21 < 0.0001
LVPWT (mm) 13 + 3 8-16 15 ±3 10-23 NS (0.16)
LVM (g) 129 ±24 98-172 145 ±41 81-205 NS
RVWT/BSA 3.7 ±0.9 2.2-4.6 7.6 ±2.9 3.1 - 15.0 < 0.0001
RVWT/LVPWT 0.5 ±0.1 0.3-0.6 0.9 ±0.3 0.4-1.9 0.0003
RVWT/LVM 0.049 ± 0.031 - 0.099 ± 0.041 - 0.0009
0.015 0.071 0.049 0.204
Echo PASP 31 ±11 16-49 75 ±33 25-144 < 0.0001
(mmHg)
Table 5B: Correlations with MPAP and sensitivity and specificity for
PAHT
Correlation with Sensitivity for Specificity for
MPAP PAHT PAHT
RVWT (mm) (n = 26) r= 0.83 89% 100%
Echo PASP (n = 26) r = 0.77 89 % 57 %
(mmHg)
FOOTNOTES:
PAHT = pulmonary arterial hypertension, BSA = body surface area, MPAP = mean pulmonary
artery pressure, CO = Cardiac output, RVWT = right ventricular wall thickness, LVPWT = left
ventricular posterior wall thickness, LVM = left ventricular mass, Echo = Doppler
echocardiography, PASP = pulmonary artery systolic pressure, SD = Standard deviation, NS =
Not significant.
102






MPAP = mean pulmonary artery pressure, RVWT = right ventricular wall thickness,
CI = confidence intervals, PI = prediction intervals
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Figure 5C: Correlation between MPAP and
RVWT/BSA
MPAP = mean pulmonary artery pressure, RVWT = right ventricular wall thickness,
BSA = body surface area, CI = confidence intervals, PI = prediction intervals
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MPAP = mean pulmonary artery pressure, RVWT = right ventricular wall thickness,
LVPWT = left ventricular posterior wall thickness, CI = confidence intervals, PI = prediction intervals
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MPAP = mean pulmonary artery pressure, RVWT = right ventricular wall thickness,
LVM = left ventricular mass, CI = confidence intervals, PI = prediction intervals
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5.4 Discussion
This study has shown that a single simple MRI measurement of right ventricular wall
thickness predicts mean pulmonary artery pressure with similar accuracy and sensitivity,
but better specificity than doppler echocardiography in primary and secondary pulmonary
hypertension. This may be because echocardiography is confounded by the known
spontaneous variability in pulmonary haemodynamics (108). Correcting for body habitus
by indexing for body surface area, left ventricular posterior wall thickness or left
ventricular mass did not improve the correlation and may be unnecessary.
Our results are similar to those previously reported using a variety of end-diastolic
methods (123, 125, 136). Saito et al chose to make their measurements on a modified
short axis section immediately under the right ventricular outflow tract, an area relatively
free from trabeculation (136). Frank et al measured wall thickness at the mid-ventricular
free wall on a four chamber view similar to that used in this study (125). Bouchard used a
calibrated grid method in the right ventricular outflow tract on a transverse section of the
heart (123, 183). We chose to make our measurements at the thickest point on a long-axis
view of the ventricle in an attempt to standardise the technique and make it less
subjective while keeping it simple and practical. We used body surface area and left
ventricular parameters to index our measurement as suggested by the literature and our
own work (Chapters 3 and 4)(172).
The normal right ventricle is a surprisingly thin walled structure. Pathological studies
estimate the normal right ventricular free wall to be about 2-4 mm thick (184).
Echocardiographic studies have reported a value of between 2 and 5 mm (177-179),
depending upon the approach and technique employed. MRI studies have been very
consistent irrespective of technique: Markiewicz reported the normal range to be 2.9 ±0.9
mm in twenty five controls (181). Frank et al found values of 2-3 mm in eight controls
(125). Suzuki et al studied nine healthy volunteers and found normal values to be 2.9
±0.8 mm (182) and Bouchard et al reported normal values of 3 ±1 mm in ten controls
(123). Our normal values were significantly higher than this. The most likely explanation
of this discrepancy is that, unlike previous investigators, we defined RVWT as being the
thickest part of the right ventricular free wall. Another possible explanation is that our
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"normals" were not true matched controls. All had been referred with a strong clinical
suspicion of pulmonary vascular disease, however its worth noting that our RVWT
values for those with PAHT are also higher than those reported.
It is not entirely surprising that measurements of right ventricular wall thickness predict
mean pulmonary artery pressure irrespective of the method used, because the right
ventricle functions as a unit and the excess load is likely to be evenly distributed. What is
unexpected is the degree of accuracy derived from single measurements of wall thickness
even without correction for body habitus, when more variation would be expected due to
oblique positioning of the scan and the inherent irregularity of the wall. Wall thickness
appears to be more accurate than uncorrected mass measurements (122, 172).
Furthermore, we know from pathological studies that right ventricular wall thickness
correlates poorly with ventricular weight (185, 186). This suggests that right ventricular
wall thickness does not depend upon body habitus and simply reflects the work of the
right ventricle. It may therefore prove to be a reliable and accurate way of detecting
pulmonary hypertension and monitoring the response to treatment. There is already
echocardiographic and MRI evidence of significant reduction in right ventricular wall
thickness within 3-12 months of single lung transplantation (129, 187) and further studies
are needed of the long term effects ofmedical therapy.
So how should this measurement be made? As described earlier, MRI has several
advantages over doppler echocardiography and this study has highlighted a further
important advantage. Echocardiography has a reported success rate of between 50% and
90% in measuring RVWT, depending upon the approach employed and the operator
(177, 179). Tsuda et al compared three techniques and reported the best to be an anterior
approach in the supine position with a success rate of only 80% (179). In contrast, we
successfully studied twenty-five out of twenty-six subjects: our only failure suffered from
acute claustrophobia (subject 7). There were no failures reported in any of the earlier
studies.
There are a number of possible sources of error in this study. No attempt was made to
blind the reporting of scans which may have led to bias, and we did not test inter and
intra-observer reproducibility. Although every effort was made to make measurements in
a plane orthogonal to the right ventricular free wall, some images may have been oblique
108
leading to higher values. Seven of our subjects had ischaemic heart disease or systemic
hypertension, possibly altering left ventricular mass and posterior wall thickness.
However there was no evidence of left ventricular dysfunction or hypertrophy at
echocardiography and right heart catheterisation. Although subjects 16,17,20 and 21 only
received supplementary oxygen during Doppler Echocardiography and right heart
catheterisation, and not during Magnetic Resonance Imaging, this is unlikely to have
affected our anatomical measurements.
In summary, this study has shown that a single simple unindexed measurement of right
ventricular wall thickness predicts mean pulmonary artery pressure with similar accuracy
and better specificity than conventional doppler echocardiography of the tricuspid valve
in pulmonary hypertension.
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6 Measurements of great vessels
6.1 Introduction
Computerised axial tomography (CT) and Magnetic resonance imaging (MRI) can be
used to make accurate measurements of the great vessels and dilatation of the main
pulmonary artery has been shown to be a marker for the presence of raised pressure (123-
125, 139-141, 188-190). In 1998 Edwards et al reported that the upper limit of normal for
main pulmonary artery diameter (MPAD) was 33.2 mm after a study of one hundred
normal subjects and twelve patients with PAHT (190). A number of studies have used
MPAD as a non-invasive method of estimating MPAP with some reporting significant
correlations (123, 125, 139-141) and others not (124, 188, 189), however there have been
no direct comparisons with Echo. The ratio ofMPAD to aortic diameter (AOD) has also
been shown to correlate with MPAP (123, 124). In a recent study, Ng et al retrospectively
reviewed the CT scans of fifty patients with a wide range of pulmonary and cardiac
diseases who had also undergone cardiac catheterisation and suggested the finding
"MPAD/AOD > 1" as an accurate sign of the presence ofPAHT (139).
In this study we set out to test the accuracy ofMRI measurements of the main pulmonary
artery and aorta in detecting and quantifying raised MPAP, using the normal limits
proposed by Edwards et al (190) and the ratio suggested by Ng et al (139). We
prospectively studied a heterogeneous group of patients referred to our centre for
investigation of suspected pulmonary hypertension. We then determined whether
adjusting for body surface area improved predictive accuracy. Finally, we made a
comparison with doppler echocardiography.
6.2 Method
6.2.1 Study subjects
Subjects were recruited as outlined in Chapter 2 and are shown in Table 2C. Subjects 27
and 28 were not included in this study because the interval between RHC and Echo of
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four weeks was considered to be too long to make an accurate comparison. Twenty-six
subjects were enrolled after informed consent was obtained. All had normal left
ventricular function and morphology at echocardiography. PAHT was defined as MPAP
of 25 mmHg or more (5).
PAHT was confirmed in nineteen subjects, of whom six had PPH, four connective tissue
disease (CTD), three congenital heart disease (CHD), two chronic obstructive pulmonary
disease (COPD), two portopulmonary disease (PP), one chronic thromboemboembolism
(CTEPHT) and one hereditary haemorrhagic telangiectasia (HHT). The remaining seven
had normal pulmonary haemodynamics at cardiac catheterisation, and had been referred
because of evidence of PAHT at Echo (subjects 4,6,11,12,25) or cardiopulmonary
exercise testing (subjects 14,23).
6.2.2 MRI Image Analysis
MPAD was taken as the largest internal diameter in millimetres of the main pulmonary
artery before bifurcation (Figure 6A). The image showing the largest MPAD was used for
analysis. AO was taken as the largest internal diameter in millimetres of the descending
aorta on the same image (Figure 6A). MPAD was adjusted for body size by dividing by
body surface area.
6.2.3 Statistical Analysis
Data was analysed using Minitab for Windows (Release 12.1). Pearson's correlation
coefficient and linear regression analysis were used to assess the relationship between
MPAP measured at cardiac catheterisation and measurements made at Echo and MRI.
Sensitivities, specificities, positive and negative predictive values were calculated. An
"intention to scan" analysis was done when calculating sensitivities and specificities.
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Figure 6A: Cross-sectional images used to
measure MPAD and AOD
MPAD = main pulmonary artery diameter, AOD = diameter of descending aorta, AO = aorta,




Twenty out of twenty-six subjects underwent MRI within two days of cardiac
catheterisation. The remaining six were scanned within two weeks (subjects 1,2,6,15,19
and 21). Measurements were successfully obtained in twenty-five subjects, but scanning
was abandoned in one subject due to claustrophobia (subject 7). All twenty-six subjects
underwent Echo within two days of cardiac catheterisation, however values are only
available for twenty-four subjects; in subject 8 PASP was raised but could not be
accurately measured, and was therefore not included in linear regression analysis; in
subject 22 PASP could not be measured. In subject 6 PASP was reported as " < 25 " and
a value of 25 was used for statistical analysis. Echo and cardiac catheter measurements
are shown in Table 2C with correlations in Table 6A. Raw MRI data is shown in
Appendix 2. Sensitivities, specificities, positive and negative predictive values are shown
in Table 6B.
Table 6A: Correlations of MRI and Echo measurements with MPAP




Echo PASP 0.77 <0.001
FOOTNOTES:
MPAD = Main pulmonary artery diameter, AOD = Diameter of descending aorta, BSA = body
surface area, Echo = Doppler echocardiography, PASP = pulmonary artery systolic pressure
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Table 6B: Sensitivities, specificities, positive and negative predictive
values for MRI and Echo measurements
Sensitivity % Specificity % Positive Negative
predictive value predictive value
% %
MPAD 79 100 100 70
MPAD/BSA 89 86 94 86
MPAD/AOD 95 57 86 100
Echo PASP 89 57 85 80
(Using MPAD > 33.2mm, MPAD/BSA > 16, MPAD/AOD > 1 and
Echo PASP > 35mmHg as indicative of pulmonary arterial hypertension)
FOOTNOTES:
MPAD = Main pulmonary artery diameter, AOD = Diameter of descending aorta, BSA = body
surface area, Echo = Doppler echocardiography, PASP = pulmonary artery systolic pressure
6.3.2 Quantification of pulmonary artery pressure
There was a significant correlation between MPAP and MPAD (r = 0.62, Figure 6B),
with a small improvement after adjusting for differences in body size (r = 0.71, Figure
6C). The closest correlation obtained was between MPAP and MPAD/AOD (r = 0.82,
Figure 6D). Agreement with Echo was less good with more scatter and wider confidence
intervals (r = 0.77, Figure 3E).
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Figure 6B: Correlation between MPAP and
MPAD
MPAP = mean pulmonary artery pressure, MPAD = main pulmonary artery diameter,
CI = confidence intervals, PI = prediction intervals
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14 16 18 20 22 24
MPAD/BSA
26 28
MPAP = mean pulmonary artery pressure, MPAD = main pulmonary artery diameter,
BSA = body surface area, CI = confidence intervals, PI = prediction intervals
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Figure 6D: Correlation between MPAP and
MPAD/AOD
MPAP = mean pulmonary artery pressure, MPAD = main pulmonary artery diameter,
AOD = diameter of descending aorta, CI = confidence intervals, PI = prediction intervals
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6.3.3 Detection of pulmonary hypertension
6.3.3.1 MPAD
If we take values of MPAD above 33.2 mm as abnormal then there would be no false
positives, three false negatives (subjects 2,5,13) and one failed scan, giving sensitivity
79%, specificity 100%, positive predictive value 100% (15/15) and negative predictive
value 70% (7/10)(Table 6B).
6.3.3.2 MPAD/BSA
If we take values of MPAD/BSA above 16 as indicative of PAHT then there would only
be one false positive (subject 6), one false negative (subject 13) and one failed scan,
giving sensitivity 89%, specificity 86%, positive predictive value 94% (17/18) and
negative predictive value 86% (6/7).
6.3.3.3 MPAD/AOD
If we take a MPAD/AOD ratio of > 1 to be abnormal then there are three false positives
(subjects 6,11,23), no false negatives and one failed scan, giving sensitivity 95%,
specificity 57%, positive predictive value 86% (18/21) and negative predictive value
100% (4/4) respectively.
6.3.3.4 Echo PASP
Taking a pressure of > 35 mmHg as abnormal, there were three false positives (subjects
4,11 and 25), one false negative (subject 13) and one failed scan (subject 22) giving
overall sensitivity 89%, specificity of 57%, positive predictive value 85% (17/20) and
negative predictive value 80% (4/5).
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6.4 DISCUSSION
Pulmonary hypertension is no longer considered an untreatable disease. As a result it is
important that any investigation has high sensitivity and negative predictive value.
Measurements of the great vessels have been suggested as an accurate method of
detecting and quantifying raised pulmonary artery pressure (139, 190). This is the first
study to compare the accuracy of these measurements with doppler echocardiography, the
current gold standard. It is also the first prospective study to show the validity of this
technique in the initial assessment of patients with both primary and secondary
pulmonary hypertension.
Although this is a small study, we have shown that measurements of the great vessels
may detect raised pulmonary artery pressure with better sensitivity, specificity and
predictive value than doppler echocardiography. A larger study will be necessary to
confirm these findings. We have also demonstrated that it may be possible to make
estimates of mean pulmonary artery pressure with greater accuracy with this technique.
This may be because doppler echocardiography is operator dependant and can be
influenced by short-term physiological variables such as heart rate, posture, hydration
status and supplementary oxygen (all of which also affect the real-time measurements
made at right heart catheterisation) (52). Anatomical measurements of the great vessels
are therefore likely to be more reproducible and may provide a more clinically relevant
assessment of disease progression or response to treatment. Furthermore, although
doppler echocardiography was successfully performed in almost all of the patients in this
study, there is a failure rate of up to 60% in some patient groups due to body habitus,
undetectable tricuspid regurgitation or co-existing lung disease (78). In comparison MRI
scans were generally well tolerated with adequate images obtained in a few minutes.
Our data are similar to those reported in earlier studies, and show similar correlations
(Table 6C). Although most previous investigators did not use the currently accepted
definition of pulmonary hypertension (mean PAP > 25 mmHg), our data can still be
compared with all except Kuriyama et al (140), since none of our normal subjects had a
mean PAP of between 20 and 25 mmHg. We found a higher sensitivity and lower
specificity for MPAD/AOD than that reported by Ng et al (139).
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Table 6C: Studies reporting correlations between measurements of the




Sensitivity Specificity r values
Kuriyama et al (n = 32)* MPAD 28.6mm 69% 100% 0.83
MPAD/BSA 0.81
Bouchard et al MPAD 0.76
(n=17)*** MPAD/AOD 0.59
Murray et al (n = 12)*** MPAD None
MPAD/AOD 0.7
Haimovici et al (n = 55)* MPAD 0.67
MPAD/BSA 0.66
Tan et al (n = 45)** MPAD 29 mm 87% 89% None
Edwards et al (n = 12)** MPAD 33.2 mm 58% 95%
Ng et al (n = 50)** MPAD 30 mm 68% 100% 0.74
MPAD/AOD 1.0 70% 92% 0.74
This study*** MPAD 33.2mm 79% 100% 0.62
MPAD/BSA 16 89% 86% 0.72
MPAD/AOD 1.0 95% 57% 0.82
FOOTNOTES:
*
= Pulmonary hypertension defined as mean PAP >18 mmHg, ** = Pulmonary hypertension
defined as mean PAP > 20 mmHg, *** = Pulmonary hypertension defined as mean PAP > 25
mmHg, MPAD = Main pulmonary artery diameter, BSA = Body surface area, AOD = Diameter of
descending aorta
This suggests that a ratio somewhat higher than the 1.0 proposed may be a better test for
the presence of raised pulmonary artery pressure. An alternative explanation would be
that our subjects differed from theirs; their study was retrospective and 32 out of 50
subjects had undergone investigation as part of a transplant assessment, whereas ours was
prospective and unselected. There have been two other prospective studies however
neither were unselected; Murray et al studied 12 adults and children with primary
pulmonary hypertension (124) and Haimovici et al reported on a group of patients
referred for a transplant assessment (141).
There are a number of weaknesses in our study. No attempt was made to blind the
reporting of scans which may have led to bias. Four of our subjects (16,17,20,21)
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received oxygen during cardiac catheterisation and echocardiography but not during
MRI. Although this could conceivably have affected the results, it would have been
expected to weaken and not strengthen our findings. MRI measurements were not made
at the same point in the cardiac cycle and vascular girth is likely to vary with the degree
of blood flow, however once again this would have been expected to reduce accuracy and
weaken our results. Our values for main pulmonary artery diameter are also similar to
those reported in previous studies (124, 189). The main pulmonary artery is short, and it
is possible that images were not taken at the point of maximum diameter, but this error
would also apply to subjects without pulmonary hypertension, and should also reduce the
discriminatory accuracy of the technique.
In summary, this prospective study has shown that a main pulmonary artery diameter of>
33.2 mm and a ratio ofmean pulmonary artery diameter over aortic diameter of > 1.0 can
be used to detect raised pulmonary artery pressure with better sensitivity and specificity
than doppler echocardiography. The ratio of main pulmonary artery diameter over aortic
diameter also correlated more closely with mean pulmonary artery pressure than doppler
echocardiography in patients with both primary and secondary pulmonary hypertension.
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7 Flow in right pulmonary artery
7.1 Introduction
One of the first investigators to consider flow was Leonardo da Vinci (1452 - 1519). He
proposed that a suspension ofparticles in a glass container could be used to study internal
currents (191), and this approach is still used in modern fluid mechanics. Blood flow is a
more complex process governed by several factors, including cardiac function, vascular
anatomy and compliance, blood viscosity and the presence of endothelial disease. MRI
has provided a versatile new clinical tool for studying blood flow non-invasively and
several different techniques have been described in the past few years. These methods
utilise one of the following MR effects: phase shift, 3D-Fourier encoding, time of flight
and in-flow/out-flow. Phase shift velocity mapping, first proposed by Moran in 1982
(192), is the most extensively validated technique in the clinical setting due to its
accuracy and easy applicability and was used in this study (193).
The principle of phase shift velocity mapping is that the MR signal of a moving target
(i.e: blood) in a magnetic field changes in proportion to its velocity and direction of travel
(phase shift). The confounding effect of a non-moving target (i.e: tissue) is eliminated by
reversing the gradient of the magnetic field for the same period of time which has the
effect of cancelling out the MR signal produced by all motionless targets. The phase
image is further "cleaned" by acquiring two phase images, one with and one without
velocity mapping. Subtracting one from the other leaves only the velocity-related phase
shifts (193).
The use of MR phase shift velocity mapping to measure flow has been validated in
phantom and animal studies (156, 158, 159). Human studies have shown good agreement
with doppler echocardiography for normal aortic blood flow (160), peak jet velocity in
patients with valve disease (157) and stroke volume and cardiac output (161).
Measurements of blood flow in the pulmonary artery and aorta show close agreement
with left ventricular stroke volume calculated as described earlier (Chapter 4) in normal
subjects (162, 163).
122
MRI has several advantages over doppler echocardiography. It can measure flow velocity
in any direction irrespective of the imaging plane. It also allows the simultaneous
measurement of vessel cross-sectional area and mean flow velocity, allowing the
calculation of volume flow and therefore stroke volume and cardiac output (193). Its
versatility makes it ideally suited for studying the complex flow patterns in the heart and
great vessels, and accurate anatomical information can be simultaneously provided for
the surgeon. In 10 to 25% of cases the main pulmonary artery cannot be imaged using
doppler echocardiography, and misalignment of the doppler signal results in
underestimation of flow velocity (194). However, like doppler echocardiography, MR
can only estimate pressure indirectly, and interventions such as vasodilator studies or
exercise studies are, at present, more easily and safely done in the cardiac catheter
laboratory.
Significant differences in flow velocities and flow time curves have been shown in the
pulmonary arteries between normal subjects and patients with pulmonary hypertension,
using both MRI and doppler echocardiography. Increased retrograde pulmonary flow,
mid-systolic notching, reduced pulmonary artery distensibility, a slower and more
irregular flow velocity profile and a decreased acceleration time (AT) and acceleration
time over ejection time ratio (AT/ET) are recognised markers of raised pulmonary artery
pressure (79, 82, 126, 127, 162, 171, 195, 196).
We wondered whether simple measurements made using MR flow quantification would
provide a clinically useful non-invasive method of detecting and quantifying pulmonary
hypertension. We therefore used MRI to measure mean velocity (MV), peak velocity
(PV), AT and AT/ET in the right pulmonary artery in patients undergoing cardiac
catheterisation to investigate suspected pulmonary vascular disease.
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7.2 Method
Subjects were recruited as outlined in Chapter 2 and are listed in Table 7A. Flow
quantification was performed at the end of the scanning protocol described earlier
(section 2.4.1) and broadly followed the method used by Marcus et al (118). An oblique
coronal image was obtained through the long axis of the right pulmonary artery (Figure
7A), using a transverse scout image on which the ascending aorta and right pulmonary
artery were both visible. An oblique sagittal image was then obtained showing a cross-
section of the right pulmonary artery (Figure 7B). This was used to generate a "flow"
image on which the circumference of the artery was manually outlined (Figure 7C) and a
flow quantification performed. The software then plotted a graph of blood flow velocity
on the y-axis against time on the x-axis using the R wave at time 0 to indicate the start of
the cardiac cycle (Figure 7D). MV was calculated by the software and PV was defined as
the maximum velocity shown by the flow curve, both expressed in centimetres per
second (cm/s). The graph was then used to calculate AT and ET as shown (Figure 7D):
AT was defined as the time between the onset of systolic blood flow and PV, and ET was
defined as the time between the onset of flow and the crossing of the x-axis by the
descending flow curve, both expressed in milliseconds (ms) (118).
The MR settings were as follows: A two dimensional gradient-echo pulse sequence was
used with excitation angle = 25 °, TE = 6.5 msec, and receiver bandwidth = 195 Hz.
Velocity sensitivity was set at 150 cm/s to avoid aliasing. Measurements were obtained
without a breath-hold. The R-R interval time was recorded by simultaneous ECG
monitoring.
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Table 7A: Patient demographics and MRI flow quantification data
Sex Age BSA Diagnosis MPAP CO PVR MV PV AT AT/
(yrs) (m2) mmHg L/min mmHg
.min/L
cm/s cm/s ms ET
1 F 40 2.01 PPH« 52 3.4 * 3.7 23.6 88 0.31
2 M 42 1.67 PPH 63 3.3 14.8 5.0 35.9 62 0.24
3 M 51 1.68 CTD 40 3.5 9.1 9.6 30.2 76 0.23
4 F 53 1.61 No PAHT 16 5.7 0.9 20.1 59.1 144 0.38
5 F 56 1.51 PPH 61 3.7 14.6 10.3 37.5 70 0.25
6 F 32 1.61 No PAHT 19 5.1 2.2 F F F F
7 F 50 1.98 CTEPHT 27 3.9 4.6 c c c c
8 F 38 1.40 CHD 78 5.5 13.5 0.1 46.7 54 0.26
9 M 29 2.00 PP 36 6.7 4.2 F F F F
10 F 44 1.77 CHD 66 4.7 * 5.7 21.8 100 0.50
11 F 54 1.72 No PAHT 15 6.0 1.3 18.6 62.5 91 0.25
12 F 42 1.51 No PAHT 19 4.1 2.2 19.5 54.7 167 0.44
13 F 58 1.82 PPH" 31 4.6 4.1 9.5 30.5 104 0.32
14 F 64 1.47 No PAHTp 16 4.4 2.3 10.9 39.2 74 0.26
15 F 33 1.63 CHD 78 6.2 11.1 4.3 23.5 100 0.34
16 M 58 1.92 CTDPx 44 2.7 * X X X X
17 F 61 1.40 CTDX 34 2.8 10.7 6.3 21.5 101 0.29
18 M 62 1.95 PPH" 53 3.6 11.1 8.2 18.1 307 0.50
19 M 51 1.86 COPD 29 3.7 4.6 F F F F
20 M 60 2.00 COPDPx 39 4.8 5.2 5.1 14.7 140 0.41
21 M 66 1.83 PPHX 40 2.6 12.7 4.0 21.7 70 0.25
22 F 31 1.92 PP 41 6.3 4.9 10.2 28.8 140 0.34
23 F 48 1.83 No PAHT 16 3.4 1.5 17.8 51.4 195 0.51
24 F 68 1.75 CTD 35 5.4 4.3 9.7 32.9 85 0.24
25 F 60 1.97 No PAHT 16 6.8 1.3 18.5 45.7 140 0.42
26 F 57 1.59 HHT 53 6.4 7.3 8.5 18.6 85 0.28
27 F 43 1.94 CTD 38 4.6 7.2 5.9 16.5 142 0.36
28 M 59 1.66 PPH 47 3.7 12.2 5.8 15.9 112 0.33
FOOTNOTES:
BSA = Body surface area, MPAP = Mean pulmonary artery pressure, CO = Cardiac output, PVR
= Pulmonary vascular resistance, MV = Mean velocity in right pulmonary artery, PV = Peak
velocity in right pulmonary artery, AT = Acceleration time, ET = Ejection time, PAHT = Pulmonary
arterial hypertension, PPH = Primary pulmonary hypertension, CTD = Connective tissue disease,
CTEPHT = Chronic thromboembolic pulmonary hypertension, CHD = Congenital heart disease,
PP = Portopulmonary hypertension, HHT = Hereditary haemorrhagic telangiectasia, " = Systemic
hypertension, 13 = Ischaemic heart disease, 1 = Long term oxygen therapy, * = Pulmonary artery
occlusion pressure unobtainable, F = Not obtainable due to technical failure, x = subject
exhaustion, c = Claustrophobia
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Figure 7D: Calculation of MV, PV, AT and ET
MV = mean velocity, PV = peak velocity, AT = acceleration time, ET = ejection time,
RPA = right pulmonary artery
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7.3 Results
Twenty-two out of twenty-eight subjects underwent MRI flow quantification within two
days of cardiac catheterisation. A further six were scanned within two weeks (subjects
1,2,6,15,19 and 21). There were no significant changes in symptoms or therapy in the
interval between MRI and cardiac catheterisation. Measurements ofMY, PV, AT and ET
were unsuccessful in five subjects due to acute claustrophobia (subject 7), exhaustion
(subject 16) and technical failure (subjects 6, 9 and 19). The data is shown along with
patient demographics in Table 7A with statistical analysis of "normal" versus PAHT in
Table 7B. Correlations between MRI and cardiac catheter data are shown in Figures 7E-
7H and Table 7C with sensitivities, specificities, positive and negative predictive values
in Table 7D.
7.3.1 Mean velocity in right pulmonary artery
There was a good negative correlation between MV and both mean PAP (r = -0.8, Figure
7E) and PVR (r = -0.79, Figure 7G). However it can be seen from Figures 7E and 7G
respectively that this is largely a result of five of the six subjects with normal mean PAP
behaving as "outliers". When the data was reanalysed after exclusion of subjects with
normal PAP a weaker correlation was obtained with mean PAP (r = -0.51) and PVR (r =
-0.47, see Table 7C). The sixth "normal" subject, who had a MV similar to those with
raised mean PAP as well as the lowest PV (subject 14), displayed an abnormal rise in
PAP with straight leg raising exercise during cardiac catheterisation. If we take a MV <
15 cm/s as indicative of PAHT then sensitivity and specificity were 100% and 83%
respectively for those actually scanned, but fell to 81% and 71% when an "intention to
scan" analysis was done. Positive and negative predictive values were 94% and 100%
respectively (Table 7D).
128
7.3.2 Peak velocity in right pulmonary artery
There was a weak negative correlation between PV and both mean PAP (r = -0.5, Figure
7F) and PVR (r = -0.52, Figure 7H). The subjects with normal mean PAP were fairly
evenly spread however both correlations became weakly positive after they were
excluded from the analysis (Table 7C), although this finding did not achieve statistical
significance. Taking a PV < 40 cm/s as indicative of PAFIT gave a sensitivity and
specificity of 94% and 83% respectively, falling to 76% and 71% after an "intention to
scan" analysis. Positive and negative predictive values were 94% and 83% respectively
(Table 7D).
7.3.3 Acceleration time and AT/ET
There were no significant correlations between AT and AT/ET and mean PAP or PVR.
Furthermore, AT and AT/ET did not differ significantly between normal subjects and
those with PAHT (Table 7B).
Table 7B: Comparison : Normals vs PAHT
Normals (n=6) PAHT (n=17) p - value
Mean ±SD Range Mean ±SD Range
MPAP 16.7 ±1.6 15-19 47.1 ±14.7 27-78 0.0000
CO 5.1 ±1.2 3.4-6.8 4.3 ±1.3 2.6-6.7 0.18
MV 17.6 ±3.4 10.9-20.1 6.58 ±2.8 0.06-10.3 0.0002
PV 52.1 ±8.6 39.2-62.5 25.8 ±8.9 14.7-46.7 0.0001
AT 135.2 ±45.6 74.0-195.0 108.0 ±57.8 54.0-307.0 0.27
AT/ET 0.37 ±0.10 0.25-0.51 0.32 ±0.08 0.23-0.50 0.29
FOOTNOTES:
MV = Mean velocity in right pulmonary artery, PV = Peak velocity in right pulmonary artery, AT =
Acceleration time, ET = Ejection time, PAHT = Pulmonary arterial hypertension, CO = cardiac
output, SD = standard deviation
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Table 7C: Correlations (r value) of MV, PV, AT and AT/ET with MPAP and
PVR
MPAP PVR
MV -0.80 (p<0.001) -0.79 (p<0.001)
MV (excluding normals) -0.51 (p=0.037) -0.47 (p=0.076)
PV -0.50 (p=0.016) -0.52 (p=0.016)
PV (excluding normals) 0.37 (p=0.147) 0.29 (p=0.302)
AT -0.26 (p=0.239) -0.27 (p=0.235)
AT/ET -0.17 (p=0.506) -0.37 (p=0.095)
FOOTNOTES:
MV = Mean velocity in right pulmonary artery, PV = Peak velocity in right pulmonary artery, AT =
Acceleration time, ET = Ejection time, MPAP = mean pulmonary artery pressure, PVR =
Pulmonary vascular resistance
Table 7D: Sensitivities, specificities, positive and negative predictive







MV 100 (17/17) 83 (5/6) 94 (17/18) 100 (5/5)
"Intention to 81 (17/21) 71 (5/7)
scan"analysis
PV 94 (16/17) 83 (5/6) 94 (16/17) 83 (5/6)
"Intention to 76 (16/21) 71 (5/7)
scan"analysis
(Using MV <15 cm/s, PV < 40 cm/s as indicative of pulmonary arterial
hypertension)
FOOTNOTES:
MV = Mean velocity in right pulmonary artery, PV = Peak velocity in right pulmonary artery
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Figure 7E: Correlation between MPAP and MV
MPAP = mean pulmonary artery pressure, MV = mean velocity,
CI = confidence intervals, PI = prediction intervals
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Figure 7F: Correlation between MPAP and PV
MPAP = mean pulmonary artery pressure, PV = peak velocity,
CI = confidence intervals, PI = prediction intervals
\32









: pulmonary artery pressure, MV = mean velocity,
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MPAP = mean pulmonary artery pressure, PV = peak velocity,
CI = confidence intervals, PI = prediction intervals
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7.4 Discussion
This study has shown significant differences in PV and MV in the right pulmonary artery
between normal subjects and those with pulmonary hypertension, consistent with the
findings of previous studies. Our flow velocity profiles (Figure 7D) show similar
phenomena to previous reports, including increased retrograde pulmonary flow and
midsystolic notching, that were not seen in the normal population (79, 82, 126, 127, 162,
195). Although there were correlations with mean pulmonary artery pressure and
pulmonary vascular resistance for the study group as a whole, these became substantially
weaker after those with pulmonary hypertension were analysed separately.
There were no significant correlations between AT and AT/ET and mean pulmonary
artery pressure and pulmonary vascular resistance, and more surprisingly, no detectable
difference between normal and pulmonary hypertensive subjects. This is inconsistent
with the published literature and requires an explanation. The sample size was small and
the subjects heterogeneous, and this coupled with the known spontaneous variability of
haemodynamic measurements in this disease (108) may provide part of the explanation.
Although our pulmonary hypertension subjects had a wide range of mean PAP their
cardiac output was relatively well preserved and our values for AT and AT/ET were a
little higher than those reported in the literature (79, 127, 196). Furthermore, our "normal
subjects" had in fact been referred for investigation because of a strong clinical suspicion
of pulmonary vascular disease: subjects 4,11,12 and 25 had abnormal doppler
echocardiography and subject 14 with the lowest AT and MV in the "normal" group had
an abnormal rise in pulmonary artery pressure during exercise testing in the cardiac
catheter laboratory.
Echocardiographic and MRI measurements of blood flow in PAHT correlate well with
cardiac output (127) but there have been no reports to our knowledge correlating velocity
to mean pulmonary artery pressure or pulmonary vascular resistance. Although we did
find significant correlations, in particular for MV, they are not close enough to be
clinically useful. This is not surprising as flow is a function of compliance and viscosity
as well as pressure and resistance, but there are other possible explanations. Our software
calculated an average mean velocity during a cardiac cycle and the average peak velocity
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at a particular time point during the cardiac cycle, in common with most commercially
available software. This might have been expected to iron out the expected irregularities
in flow across the chosen cross-section of right pulmonary artery, but might have had a
"dampening" effect on the data, especially if a portion of vessel wall was included when
the image was manually outlined. The use of the right pulmonary artery rather than the
pulmonary trunk may have contributed to this effect. Although pulmonary artery
distensibility is reduced in pulmonary hypertension (162), changes in vessel cross-
sectional area relative to the outlined image may have been significant leading to
inaccuracy. A more serious source of inaccuracy are the increased retrograde pulmonary
systolic flow and mid-systolic notching seen in pulmonary hypertension (79, 126, 162)
which are likely to affect MV and PV in an unpredictable way. The right pulmonary
artery is not always straight in its course and although care was taken to obtain a true
cross-section, an oblique image might inadvertently have been used. Finally, although
right and left pulmonary artery blood flow is approximately equal in normal subjects
(128), this may not be true in pulmonary hypertension.
The lack of a correlation between AT and AT/ET and mean PAP and pulmonary vascular
resistance is less surprising. Although initial echocardiographic studies of AT/ET
reported a good correlation with the degree of pulmonary hypertension (79, 80, 83, 197),
this was not borne out in later studies (87, 196). Although Tardivon et al reported a good
correlation with AT measured by MR, there was no correlation in patients with a mean
PAP between 45 and 60 mmHg, and all but three of their patients fell within this range
(127). Marcus et al only reported a correlation for AT/ET with systolic PAP in a sample
of 11 subjects (171).
In summary, this study has shown that MR measurements of mean and peak blood flow
velocity in the right pulmonary artery can be used to detect and quantify pulmonary
artery pressure and pulmonary vascular resistance with limited accuracy. MR
measurements of AT and AT/ET showed no significant differences between normal
subjects and those with pulmonary hypertension.
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8 Exercise MRI pilot study
8.1 Introduction
Stress testing is an important part of the assessment of the cardiopulmonary circulation
for a number of reasons. It may reveal the presence of diminished reserve or early
disease. It may also provide a useful clinical marker of disease severity and response to
treatment, and several recent trials of new therapies have used six minute walk testing as
a primary endpoint (27, 36). Furthermore, although the predominant symptom
experienced by patients with pulmonary hypertension is exercise intolerance, this is not
always predicted by resting pulmonary haemodynamics at right heart catheterisation
(101), and may relate in part to exercise-induced changes in pulmonary artery blood flow.
MRI velocity mapping is an accurate and reliable method of measuring blood flow at rest
(see Chapter 7). A number of studies have also reported success in measuring blood flow
during or shortly after exercise or pharmacologically induced stress. Significant changes
in blood flow have been demonstrated in the tibeal and popliteal arteries after ankle
exercise in normal subjects and those with suspected peripheral vascular disease (198,
199). Pennell et al used dobutamine stress testing to evaluate left ventricular function by
studying aortic blood flow curves in 25 subjects suspected of having coronary artery
disease (200). Mohiaddin et al used a breathhold technique to measure blood flow in the
descending thoracic aorta before and after supine exercise using a home made pedaling
apparatus (201). MR compatible supine cycle ergometry is now available and has been
successfully used to measure blood flow in the aorta and pulmonary artery during
exercise in normal volunteers without a breathhold (202), although there have been
difficulties with movement artefact and ECG triggering accuracy (203).
To our knowledge, there have been no attempts to study exercise-related changes in
pulmonary artery blood flow in patients with pulmonary hypertension using MRI velocity
mapping. We therefore undertook this pilot study to see whether MRI flow quantification




All subjects who underwent MRI flow quantification in our previous study were eligible,
however because the exercise flow quantification protocol was only instituted at a later
date, enrolment only began with subject twenty-one. We initially attempted to perform
adequate exercise by means of a pedalling machine designed and built with the help of
the department of medical physics, however bedside testing showed that the work load
generated in this way was not sufficient to adequately raise heart rate. We therefore
decided to use straight leg raising (SLR), modifying the protocol used routinely in our
cardiac catheter laboratory. Following acquisition of resting flow measurements as
described in the last chapter, subjects were asked to maintain the same position while
their bed was moved out of the scanner. After recording the resting heart rate subjects
were asked to perform three minutes of SLR exercise by lifting each leg alternately as
high as possible while keeping it extended. This was supervised with suitable vocal
encouragement. As soon as three minutes of SLR was completed or the subject became
exhausted the bed was moved back into the scanner and a further flow quantification
performed in the right pulmonary artery, using the same MRI settings as before. The data
was then analysed as previously described.




Eight subjects were enrolled, two with PPH, two with CTD, one with PP, one with HHT
and two with normal MPAP at cardiac catheterisation (Table 8A). The interval between
cardiac catheterisation, 6mwt and MRI scanning was less than 2 days in all except
subjects 27 and 28 where it was four weeks. Exercise MRI flow measurements were only
obtained in four subjects, two with PPH (subjects 21 and 28) one PP (subject 22) and one
with normal haemodynamics (subject 23) and the results are shown in Table 8B. Three
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subjects preferred not to do any exercise at the end of the MRI protocol due to back pain
(subjects 26 and 27) or exhaustion (subject 24). Measurements were not possible in
subject 25 because the exercise resulted in her being out of position and flow
quantification could not be performed.
Table 8A: Patient demographics, diagnoses and MRI flow data at rest
Sex Age Diagnosis MPAP CO PVR MV PV AT AT/ 6mwt
yrs mmHg L/min mmHg
.min/L
cm/s cm/s ms ET m
21 M 66 PPHX 40 2.6 12.7 4.0 21.7 70 0.25 210
22 F 31 PP 41 6.3 4.9 10.2 28.8 140 0.34 260
23 F 48 No PAHT 16 3.4 1.5 17.8 51.4 195 0.51 550
24 F 68 CTD 35 5.4 4.3 9.7 32.9 85 0.24 345
25 F 60 No PAHT 16 6.8 1.3 18.5 45.7 140 0.42 360
26 F 57 HHT 53 6.4 7.3 8.5 18.6 85 0.28 350
27 F 43 CTD 38 4.6 7.2 5.9 16.5 142 0.36 263
28 M 59 PPH 47 3.7 12.2 5.8 15.9 112 0.33 438
Table 8B: Exercise MRI Flow Data
HR SLR HR MV PV AT AT/ Comments
(rest) duration (s) (After SLR) cm/s cm/s ms ET
21 80 180 128 4.5 20.5 91 0.30
22 70 120 120 10.6 26.0 140 0.36
23 60 180 80 23.1 66.3 165 0.46
24 64 No SLR (exhaustion)
25 94 150 125 Out of position after
SLR
26 108 No SLR (back pain)
27 67 No SLR (back pain)
28 69 180 87 7.2 22.5 95 0.27
FOOTNOTES:
MPAP = Mean pulmonary artery pressure, CO = Cardiac output, PVR = Pulmonary vascular
resistance, MV = Mean velocity in right pulmonary artery, PV = Peak velocity in right pulmonary
artery, AT = Acceleration time, ET = Ejection time, 6mwt = Six minute walk test, PAHT =
Pulmonary arterial hypertension, PPH = Primary pulmonary hypertension, CTD = Connective
tissue disease, PP = Portopulmonary hypertension, HHT = Hereditary haemorrhagic
telangiectasia,1 = Long term oxygen therapy, SLR = Straight leg raising exercise
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8.3.2 MRI flow measurements
There was a significant rise in heart rate (over 25%) following exercise in all four
subjects. Although subject 22 did not manage three minutes of SLR, she had the largest
rise in heart rate, signifying good effort. In subjects 23 and 28 both MV and PV rose,
whereas in subjects 21 and 22 MV rose and PV fell (Figure 8A). This suggests a
flattening of the flow velocity profile in subjects 21 and 22 (Figure 8A). Similarly, AT
and AT/ET fell in subjects 23 and 28, whereas they rose or remained unchanged in
subjects 21 and 22 (Figure 8A).
8.3.3 6mwt
Exercise tolerance was relatively well preserved in both subjects 23 and 28, whereas it
was poor in subjects 21 and 22 (Table 8A).
8.4 Discussion
This small pilot study suggests that it may be possible to use MRI velocity mapping to
assess changes in blood flow in the pulmonary circulation following exercise. It should
be emphasised that this is very preliminary data on a small number of subjects and
therefore should be interpreted with caution, however taken at face value our results
suggest that resting pulmonary haemodynamics may not predict changes in blood flow
velocity profiles in this group of patients. As predicted by his good exercise tolerance,
subject 28 appeared to have a similar change in flow velocity profile to subject 23 who
had normal haemodynamics, in spite of having a similar mean pulmonary artery pressure
to subjects 21 and 22. This difference is not explained by resting cardiac output or
pulmonary vascular resistance, as can be seen from table 8A. We know that the
magnitude of the rise in pulmonary artery pressure with exercise is not predicted by
resting haemodynamics (52), and it is plausible that flattening of the flow velocity profile
occurs in those patients with a greater rise in pressure. More work needs to be done to
validate these findings and assess the feasibility of this approach.
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Figure 8A: Exercise-related changes in















SUBJECTS 23 AND 28
REST EXERCISE
REST EXERCISE
SUBJECTS 21 AND 22
MV = mean velocity, PV = peak velocity, AT = acceleration time, ET = ejection time
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Stress testing is potentially hazardous in patients with pulmonary hypertension. The
normal pulmonary circulation is remarkably compliant and can cope with a six-fold rise
in cardiac output with minimal change in mean pulmonary artery pressure (102). This
compliance is lost in pulmonary vascular disease and pulmonary artery pressure rises
rapidly with exercise. The extent of this rise is not predicted by resting pulmonary
haemodynamics (52). Left ventricular filling is also impaired due to right ventricular
pressure overload (171), and this coupled with rising pulmonary artery pressure
eventually results in a reduction in left ventricular filling. This in turn results in falling
cardiac output and syncope. A further complication is right ventricular ischaemia caused
by the increasing oxygen demand of the hypertrophied right ventricle, and this may
provoke potentially fatal arrhythmias. In spite of this, several studies have subjected
patients with pulmonary hypertension to symptom-limited exercise testing with few
adverse events reported (204), and cardiopulmonary exercise testing has been advocated
as a sensitive test for detecting and quantifying pulmonary vascular disease (103), and
providing prognostic information (205). There were no adverse events in our study, and
although three out of our eight subjects were intolerant of our stress testing protocol, this
is unlikely to be a problem with better patient selection.
The cardiopulmonary circulation can be stressed in two ways: the subject can be asked to
perform real physical exercise, or stress can be induced pharmacologically using
dobutamine, dipyridamole or adenosine (206). Physical exercise has several advantages:
it is of direct clinical relevance to the patient, is non-invasive and physiologically
accurate, and the subject remains in control of the situation, which can be seen as an
added safety feature. Disadvantages, including motion artefacts and ECG-triggering
difficulties (203) can be overcome by real-time image acquisition of images, however
this was not widely available on commercial scanners at the time of writing.
Pharmacological stress testing has been shown to be safe and well tolerated in the
assessment of coronary artery disease (206) but there is little data on the safety of this
approach in pulmonary vascular disease. Tulevski et al used dobutamine stress MRI to
study forty-seven subjects with chronic right ventricular pressure overload due to
transposition of the great arteries or a subpulmonic right ventricle. They reported only
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one arrhythmic event and three episodes of nausea and vomiting (207), but there have
been no other relevant published studies.
In summary, this pilot study has shown that it may be possible to use MRI velocity
mapping to measure exercise related changes in pulmonary artery blood flow in
pulmonary hypertension. Studying these changes may help in understanding the




Magnetic resonance imaging is an exciting and innovative form of imaging with an
expanding list of clinical applications. It has the potential to make non-invasive
anatomical and physiological measurements reliably and accurately in the vast majority
of subjects without recourse to radiation in almost every field of medicine, from
cardiology to neurology. It can be used as an alternative to post mortem studies (208)
with obvious advantages in children and those with particular religious beliefs. As the
technology advances, with ever faster and more compact scanners becoming available,
the problems of claustrophobia, noise and limited access are being addressed. Costs are
coming down but still limit availability at the time ofwriting.
Pulmonary hypertension is a rare disease with, until recently, a poor prognosis. The
plethora of new therapies that have recently become available have reinforced the need
for objective and accurate methods of monitoring disease progression and response to
treatment. As discussed in the Introduction, there are good reasons why assessments of
pulmonary haemodynamics and exercise capacity alone are likely to be inadequate. MRI
can provide a holistic approach to the assessment of the cardiopulmonary circulation. A
single examination can provide accurate and reproducible measurements of right
ventricular morphology, including mass, wall thickness and chamber volume and also of
the great vessels in the cardiopulmonary circulation. These measurements can be used to
estimate pulmonary artery pressure with similar or better accuracy than doppler
echocardiography, and have the advantage ofproviding a measure of the recent burden of
pulmonary vascular disease without being influenced by transient physiological variables.
An analogy may be made with the use of glycosylated haemoglobin instead of blood
glucose to assess glycaemic control in diabetics (166). Measurements of resting and
exercise blood flow can be made, and can also be used to detect and quantify pulmonary
hypertension. Diagnostic information can be simultaneously obtained at the same sitting:
MRI can be used to detect congenital heart disease (209-211), chronic thromboembolic
disease (212) and is likely to detect pulmonary veno-occlusive disease with similar
accuracy to CT.
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MRI does have limitations but was well tolerated by almost all our subjects. The
problems of noise, claustrophobia and prolonged breath-holding are fast diminishing with
advancing technology. The presence of unsecured ferromagnetic material in the body
remains a contraindication. Many patients with pulmonary hypertension are treated with
continuous intravenous or subcutaneous prostanoids requiring a syringe pump, which
would have to remain outside the scanning room, but this has already been overcome in
some departments by having syringe drivers built in to the fabric of the scanner. MRI-
compatible monitoring equipment such as pulse oximetry and electrocardiography is
already commercially available, which may soon allow pharmacological interventions to
be made more safely in the scanner. Experience with dobutamine stress testing in
ischaemic heart disease has shown it to be safe and practical (206) and there is no reason
why acute vasodilator testing could not be done non-invasively using MRI once criteria
for defining "responders" and "non-responders" in terms of changes in blood flow rather
than pressure and resistance are agreed.
Pulmonary hypertension is a rare disease with a relatively small number of sufferers, and
the costs of treatment are high. The recent designation of specialist Pulmonary Vascular
Units in the UK means that the care of these patients should now be concentrated at these
five centres (213). In this context, the cost and availability ofMRI should not be limiting
factors. MRI is already being used routinely in the pre and post-operative assessment of
patients with chronic thromboembolic pulmonary hypertension and following
transplantation (129, 130, 214, 215). It is likely to become the non-invasive investigation
of choice for all patients with pulmonary hypertension in the near future, with doppler
echocardiography reserved for initial screening where resources are unavailable.
Future work should be concentrated in a number of areas. We need to know how quickly
abnormalities of right ventricular morphology evolve in pulmonary hypertension,
whether this process can be reversed. MRI provides the best method currently available
ofmonitoring this process, and has already been used to demonstrate remodelling of the
right ventricle after single lung transplantation (129, 130, 214). We also need to know
whether these anatomical abnormalities have any prognostic significance, as suggested in
Chapter 4. MRI also provides a great opportunity to study exercise-induced changes in
right ventricular function and blood flow. This may help to explain differences in
145
exercise tolerance between patients with right ventricular overload, with or without
pulmonary hypertension, such as those with chronic obstructive pulmonary disease.
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Appendix 1 Patient information sheet
This Sheet Has Been Approved By The West Ethics Committee
Information Sheet For Patients/Volunteers In Clinical Research Project
Brief Title ofProject Ambulatory Pulmonary Artery Pressure Monitoring in Pulmonary
Hypertension : Relationship with Variables Derived from
Cardiopulmonary Exercise Testing and Magnetic Resonance
Imaging.
Patient's Summary
We invite you to participate in a trial of measurement of the blood pressure in the lung
circulation. We believe that you have raised lung blood pressure which may be the cause of some
or all of your breathlessness, and you are due to have a test called "right heart catheterisation"
soon to further investigate this. This should already have been explained to you.
This condition is difficult to diagnose and monitor, and we are searching for a safe, non¬
invasive method that may eventually replace the right heart catheter in the future. There is good
evidence that modern exercise testing or magnetic resonance imaging (MRI) may provide this.
We have developed a technique which allows us to measure the lung blood pressure
continuously during normal daily activities, including exercise and sleep. This method involves
leaving the right heart catheter in place and recording the data on a small portable tape recorder
and has been shown to be reliable. The recorder weighs less than 2 pounds and you are free to
move about normally with it. The right heart catheter will be positioned in a vein in the right side
of the neck and covered with a dressing. It will be left in overnight and removed the following
afternoon, when the data will be downloaded onto a computer and analysed. The whole procedure
will be supervised by Dr Peacock who has experience of over 50 studies using this method. There
have been no additional side effects to date from leaving the catheter in overnight, apart from
discomfort in the side of the neck in some people while it is in place, although there is a
theoretical risk of infection, blood clots or heart rhythm problems.
While the catheter is in you will have a gentle exercise test on a bicycle during which we
will make simple measurements of breathing and heart rhythm. This will be stopped as soon as
you become tired. We may ask you to do this twice, with and without oxygen, after resting for at
least half an hour.
You will also have an MRI scan to look at the heart and lungs while you do some simple
exercises. This involves lying down on a bed in a large metal tube while a magnetic field is used
to take pictures of your heart. It has no side effects and involves no radiation, but it can be noisy
and claustrophobic.
We plan to compare the results from the exercise test and MRI with those from the
catheter to see if they are reliable.
You should not take part if you are pregnant. It should be noted that your participation in
this study may not be of direct benefit to you, but could help in the development of treatment for
the benefit of future patients. Your stay in hospital may be prolonged by up to one day.
If you do not wish to participate in this study, or wish to withdraw at any time after
commencing the trial, your care will in no way be affected.
If you wish to take part in this study, your General Practitioner will be advised of your
participation and the clinical management that you will undergo.




FORM OF CONSENT FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH
PROJECT
Title ofProject: Ambulatory Pulmonary Artery Pressure Monitoring in
Pulmonary Hypertension : Relationship with Variables
Derived from Cardiopulmonary Exercise Testing and
Magnetic Resonance Imaging
By signing this form you give consent to your participation in the project whose title is at
the top of this page. You should have been given a complete explanation of the project to
your satisfaction and have been given the opportunity to ask questions. You should have
been given a copy of the patient information sheet approved by the West Ethics
Committee to read and to keep. Even though you have agreed to take part in the research
procedures you may withdraw this consent at any time without the need to explain why




give my consent to the research procedures above, the nature, purpose and possible





Appendix 2: Anatomical raw data obtained at MRI
RVM LVM VMI RVEDV LVEDV RVWT LVPWT RVWT/ MPAD AOD MPAD/
M (g) (ml) (ml) (mm) (mm) LVPWT (mm) (mm) AOD
1 173.9 160.9 1.08 132.9 67.8 16 23 0.70 46 23 2.00
2 142.3 158.1 0.90 135.6 70.2 16 17 0.94 32 20 1.60
3 90.9 122.6 0.74 68.8 78.9 13 14 0.93 39 21 1.86
4 72.3 98.0 0.74 95.2 96.5 7 12 0.58 21 24 0.88
5 85.9 80.5 1.07 79.8 51.1 16 16 1.00 30 17 1.76
6 64.2 125.3 0.51 109.2 84.6 6 13 0.46 30 21 1.43
7 c c c c c c c c c c c
8 130.5 103.2 1.26 57.1 51.3 21 11 1.91 34 18 1.89
9 138.0 187.1 0.74 142.0 F 11 12 0.92 37 21 1.76
10 144.6 105.4 1.37 108.2 64.6 11 18 0.61 38 19 2.00
11 46.5 109.5 0.42 110.1 71.2 7 12 0.58 22 17 1.29
12 71.4 130.8 0.55 104.9 91.6 4 15 0.27 22 23 0.96
13 62.6 92.4 0.68 99.0 83.3 6 10 0.60 27 26 1.04
14 31.3 139.9 0.22 51.6 79.3 6 15 0.40 15 25 0.60
15 94.1 97.3 0.97 77.3 59.8 17 17 1.00 38 16 2.38
16 sob sob sob ND ND 11 sob sob 41 31 1.32
17 121.8 128.3 0.95 93.3 63.3 10 13 0.77 34 26 1.31
18 172.2 183.6 0.94 ND ND 16 sob sob 34 22 1.55
19 135.7 192.4 0.71 ND ND 13 17 0.76 34 24 1.42
20 152.9 204.1 0.75 ND ND 12 13 0.92 36 31 1.16
21 165.2 152.3 1.08 154.3 68.0 16 14 1.14 38 31 1.22
22 91.8 147.7 0.62 108.4 94.3 6 15 0.40 35 21 1.67
23 66.4 128.2 0.52 91.3 78.9 4 8 0.50 24 23 1.04
24 77.2 141.4 0.55 118.1 90.3 8 12 0.67 39 25 1.56
25 107.2 172.7 0.62 121.5 93.2 9 16 0.56 28 29 0.97
26 160.0 205.0 0.78 155.0 80.6 17 17 1.00 44 26 1.69
27 114.0 202.1 0.56 145.4 109.1 9 16 0.56 42 26 1.62
28 143.0 155.0 0.92 117.2 69.5 14 16 0.88 34 24 1.42
FOOTNOTES:
RVM = right ventricular mass, LVM = left ventricular mass, VMI = ventricular mass index, RVEDV
= right ventricular end-diastolic volume, LVEDV = left ventricular end-diastolic volume, RVWT =
right ventricular wall thickness, LVPWT = left ventricular posterior wall thickness, MPAD = main
pulmonary artery diameter, AOD = diameter of descending aorta, c = claustrophobia, F =
technical failure, sob = failed due to breathlessness, ND = not done due to failure of ECG gating.
